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Abstract 
 
A full-length amino acid sequence of striated muscle obscurin (720-870 kDa) was 
first reported over a decade ago. It belongs to the group of giant proteins that include 
titin (~3600 kDa) and nebulin (700-900 kDa), and was first reported as a binding 
partner of titin. The obscurin gene (OBSCN) can produce multiple alternatively 
spliced isoforms, including two large isoforms: obscurin A (~720 kDa) and obscurin 
B (~870 kDa); as well as small kinase isoforms (~70-120 kDa). Remarkably for a 
sarcomeric protein, obscurin binds to and influences the structure and functions of 
cardiomyocyte membranes, including the sarcoplasmic reticulum, sarcolemma, 
intercalated disc, and perinucleur region. In animal models of the heart, the location 
of the N-terminal region of obscurin is in the M-line. The C-terminal region has been 
found to localise at both the M-line and Z-disc.  
We have investigated the effect of obscurin mutations on the expression levels of 
smaller kinase isoforms of obscurin – using confocal fluorescence microscopy. 
Antibodies to both the N and C-terminal ends of obscurin were used to determine the 
exact location of the protein in human LV cardiomyocytes.  
By comparing the level of fluorescence intensity of obscurin between mutants and 
their age-matched donors, it was found that there was a significant difference. This 
led to the conclusion that obscurin mutations significantly affect the normal 
expression of obscurin in human LV tissue. In addition, co-staining of obscurin with 
other sarcomeric proteins led to the finding that obscurin localises to the Z-disc and 
M-line, as well as the intercalated disc and the perinuclear region. These localisation 
results correlated with previous findings in animal models.   
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Prelude 
The human heart is a significant organ of the body, as it is responsible for supplying 
oxygen to the systemic circulation and the lungs .The lungs return oxygenated blood 
back to the heart. When the heart fails, it is unable to adequately supply blood to the 
body tissue. A study in 2012 by the Australian Bureau of Statistics found that 
cardiovascular diseases cause the highest number of deaths in Australia 
(approximately 30%).  
The human heart can fail from either acquired or genetic causes. Gene mutations can 
result in premature death, and ultimately, transplantation is the only effective 
treatment. Defective proteins resulting from gene mutations have been directly 
implicated in causing cardiomyopathies (heart failure).  Recently, mutations were 
discovered in the obscurin gene (OBSCN), in patients with idiopathic dilated 
cardiomyopathy (IDCM) (Marston et al., 2015).  This raises the possibility that 
obscurin may add to the pool of proteins that cause heart failure.   
The focus of this thesis is to determine whether OBSCN mutations affect its normal 
expression in the human myocardium. This thesis also investigates the locations of 
several obscurin isoforms in the human heart, which is a study that has only been 
done in animal models (eg. Bang et al., 2001; Borisov et al., 2004; Borisov et al., 
2008; Young et al., 2001).  
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1.1 The Structure of the Human Heart 
1.1.1 Anatomical review 
Anatomically, the heart is divided into the right and left side. The right side pumps 
blood to the pulmonary circulation, while the left side pumps blood through the 
body‟s systemic circulation. The heart consists of the right chambers – right atrium 
(RA) and right ventricle (RV); and the left chambers – left atrium (LA) and left 
ventricle (LV). The atria are separated by the thin interatrial septum (IAS) and the two 
ventricles are separated by the interventricular septum (IVS). 
1.1.2 The left ventricle 
The LV forms the left border and the apex of the heart. This chamber receives 
oxygenated blood from the LA. In systole, contraction of the LV results in the 
ejection of blood into the systemic circulation.  Its walls are three times thicker than 
the RV wall. This difference in wall thickness is seen in Figure 1.1. The inner surface 
exhibits muscular struts called trabeculae carnae and larger papillary muscles (usually 
two) attach to the free edges of the bicuspid mitral valve. These valves prevent 
backflow into the LA.  
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1.1.3 Tissue layers of the heart 
The ventricular walls consist of three layers (Figure 1.1). The inner layer 
(endocardium) comprises connective and endothelial tissue. The middle layer 
(myocardium) contains overlapping bundles of cardiomyocytes (heart cells). The 
outer layer (epicardium) consists of the serous pericardium.  
Figure 1.1 Image of a healthy human heart. The inner wall of the LV has ridge-like struts, the 
trabeculae carnae. The RV appears small here due to the sectional angle. The ventricles are 
separated by the IVS. The LV wall is approximately three times thicker than that of the RV. 
[Image from Seidman and Seidman, 2001, with permission] 
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1.2 Microstructure of the Heart 
 
1.2.1 Histology of the heart 
The cardiomyocyte (CM) typically has a single nucleus. Each CM is approximately 
80-120 µm long, and 10-40 µm wide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CMs are commonly branched and join adjacent CMs via the intercalated discs (ICDs).  
Intercellular junctions in the ICDs propagate action potentials between 
cardiomyocytes, enabling all the CMs within the chamber to contract almost 
synchronously.  
Figure 1.2 H &E stain of LV tissue from a donor human heart. Cardiomyocytes (pink) are 
attached to one another by intercalated discs (black arrows).  Cardiomyocytes commonly branch 
(encircled region). The striations of myofibrils are also evident in this image. The nuclei of 
cardiomyocytes appear purple. [Imaged using an Olympus/MBF Stereo Investigator Transmitted 
Light Microscope, at 40x (NA 0.75) objective] 
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1.2.2 The sarcomere 
The sarcomere is the basic contractile unit of a cardiomyocyte.  
 
 
 
 
 
 
 
 
 
 
Figure 1.3 (A) An electron micrograph of a cardiac sarcomere. The A bands stain dark, and the I-
bands appear light and short; a characteristic of cardiac sarcomeres. (B) Schematic illustration of a 
sarcomere defined by two adjacent Z-discs. The mid-point of the sarcomere is the M-line. The 
thick and thin filaments are the contractile apparatus of the sarcomere. There is a third filament, 
known as titin (blue), which begins at the Z-disc, and ends at the M-line. For simplicity, it is 
shown in one half-sarcomere. The sarcomere is also divided into distinct regions: the H-band 
(between the ends of the thin filaments), I-band (containing thin filaments and bisected by the Z 
disc), and A-band (bisected by the M line and containing thick and thin filaments). [Image (A) 
obtained from Wilson et al., 2014, with permitted use] 
 
(B) 
(A) 
0) 
A-bands I-bands Z-disc 
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Figure 1.3 illustrates a cardiac sarcomere. A series of sarcomeres form one myofibril. 
Myofibrils bundle together to form cardiomyocytes (heart cells). Each sarcomere is 
defined by adjacent Z-discs (Figure 1.3). It contains two half I-bands. The A-band is 
the largest region and contains both thin and thick filaments. In the electron 
microscope it is densely stained, while the I-band is lighter. The lateral alignment of 
myofibrils gives muscle its characteristic striated appearance (Figure 1.2). The H-
band (Figure 1.3B) is the central zone of the sarcomere and contains myosin thick 
filaments bisected by the M-line. A third myofilament, titin, was initially named 
connectin by Maruyama et al., 1977. Each titin molecule (Figure 1.3B) has its N-
terminus at the Z-disc, and anchors at its other end (C-terminus), to the M-line. In this 
way, titin spans the entire length of the half-sarcomere.  
1.2.2.1 The cardiac M-line 
The M-line bisects each sarcomere, and is a region where myosin thick filaments are 
cross-linked to one another (Agarkova and Perriard, 2005; Al-Khayat et al., 2010). 
These connections form M-line bridges (Luther and Squire, 1978). A functionally 
significant protein of the M-line is myomesin (190 kDa), which directly interacts with 
myosin, to help form these bridges. Myomesin interacts with the giant protein titin.  
Disruptions to this complex have been shown to decrease sarcomeric stability 
(Weinert et al., 2006). Myomesin also interacts in a separate complex that involves 
both titin and obscurin (Pernigo et al., 2010). This complex is important to the 
function and stability of the M-line (Fukuzawa et al., 2008; Pernigo et al., 2010). 
Down regulation of myomesin affects M-line development, and prevents the 
localisation of obscurin to the M-line (Fukuzawa et al., 2008).  
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1.2.2.2 The cardiac Z-disc 
The Z-disc is found in the middle of the I-band, and is approximately 100 nm wide in 
cardiac sarcomeres (Knöll et al., 2011). It contains a significant number of α-actinin 
molecules, which cross-link thin filaments to the Z-disc (Frank et al., 2006). Myosin 
thick filaments are not associated with the Z-disc (Frank and Frey, 2011). One of the 
primary functions of the Z-disc is to anchor titin, actin, and nebulin filaments (Knöll 
et al., 2011).  Protein complexes within the Z-disc, such as the telethonin/muscle LIM 
protein interaction, are vital to the normal functioning of the sarcomere (Knöll et al., 
2002).  
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1.3 The Intercalated Disc 
The intercalated disc (ICD) extends across the diameter of a cardiomyocyte (Lentz, 
1971). It facilitates signal transduction and transfer of electrical and chemical signals 
between cardiomyocytes (Wilson et al., 2014). It also serves a mechanical role, 
preventing cardiomyocytes from separating due to the large forces produced during 
ventricular contraction. ICDs are also vital to cardiomyocyte growth and the 
incorporation of new sarcomeres (Bennett 2012).  
 
 
 
 
 
 
 
 
Figure 1.4 Electron micrograph of cardiac intercalated discs. The fascia adherens 
junctions are found in the plicate regions (PI). There are also longitudinal membranous 
sections of the ICD (L). Gap junctions (not shown here) are concentrated at the longitudinal 
membranes, but are also found within the zones of the ICD (Severs 1994). Mitochondria are 
also present in this thin section of cardiac tissue. The A-bands appear dark, and the I-bands 
appear light. The Z-discs and M-lines are labelled. [Image from Severs 1994, with 
permission] 
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In addition, there are longitudinal membranous sections of the ICD (Figure 1.4, L). 
The transverse and longitudinal folds of the ICD mean that the structure extends 
across cardiomyocytes in a step like irregular fashion (Severs 1994), rather than in a 
straight line (Lentz 1971). 
Structurally, the ICD has four functional zones: Adherens junction (AJ) (Fascia 
adherens); Desmosome (macula adherens); Gap junction (GJ); and the Transitional 
junction. The ICD protein network consists of over 200 proteins, and approximately 
40% of them are altered in heart disease (Estigoy et al., 2009). The structural 
appearance of the adherens junction (a), desmosome (d), and gap junction (g), are 
shown below in Figure 1.5.   
 
 
 
 
 
 
 
 
  
Figure 1.5 Electron micrograph of intercalated disc junctions. This image provides a closer 
look at the structural nature of the ICD, particularly its irregularity (a) Adherens junctions, are 
found on the slopes of the folds in the plicate regions. Actin thin filaments from adjacent 
cardiomyocytes insert into the AJ (d) Desmosome. This junction provides the major 
mechanical attachment between cardiomyocytes (g) A gap junction within the transverse 
region of the ICD. The transfer of electrical and chemical signals occurs at this junction. The 
black arrowhead represents a fold of the ICD that is uncharacterised. The hollow arrowhead 
points to the last myofibrils that attach to the ICD. [Image from Bennett et al., 2006, with 
permission]  
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1.3.1 Adherens junctions (fascia adherens) 
Actin thin filaments insert into the AJ, firmly anchoring myofibrils to the ICD (Wang 
et al., 2012). They are part of the plicate regions that extend laterally in a tread-like 
fashion (Severs 1994). These treads grow in size between two weeks of age and 
maturity, and this growth is thought to occur in conjunction with the lateral growth of 
cardiomyocytes (Wilson et al., 2013). The large network of proteins within the AJ 
includes N-cadherin, which connects actin thin filaments of one cell, to cadherins in 
adjacent cells (Mezzano and Sheikh, 2012). This forms strong intercellular contacts. 
N-cadherin is also vital in anchoring the gap junction protein connexin-43 (Section 
1.3.3) to the cell membrane (Luo Y et al., 2003). 
1.3.2 Desmosomes (maculae adherens) 
Desmosomes provide the major mechanical link between cardiomyocytes. They 
contain a number of junction proteins including plakoglobin, desmoplakin, 
plakophilin-2, desmoglein-2, and desmocollin-2 (Basso et al., 2012). Mutations in 
genes encoding these proteins lead to arrhythmogenic cardiomyopathy (AC) (Basso et 
al., 2012).  In AC, there is both damage to and loss of cardiomyocytes that may result 
in sudden cardiac death (Vite and Radice, 2014).  
1.3.3 Gap junctions 
Gap junctions (GJ) are found in the transverse segment of the ICD, but are more 
prominent in the longitudinal membranes of the disc (Severs 1994). The 
oligomerisation of connexin proteins forms hexameric structures known as connexons 
(Kumar and Gilula, 1996). Connexons from adjacent cells attach to one another to 
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form specialised channels, known as GJ channels (Jongsma and Wilders, 2000; 
Kumar and Gilula, 1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GJ channels allow the passage of ions and other molecules between cardiomyocytes 
(Delmar and Liang, 2012), and help propagate action potentials (Rohr 2004). In 
cardiomyocytes, connexons comprise connexin-40 (Cx40), connexin-43 (Cx43), or 
connexin-45 (Cx45), and can be formed by a mix of these three proteins (Jongsma 
and Wilders, 2000; Severs et al., 2008). Recent evidence has also shown that small 
obscurin isoforms associate with connexin-43 (Ackermann et al., 2012).  
 
Figure 1.6 Schematic illustration of a gap junction channel Connexons from 
adjacent cells associate with one another to form GJ channels. Each connexon 
structure consists of six connexin proteins. GJ channels allow the transfer of action 
potentials, and the passage of ions. [Modified from Kumar and Gilula, 1996, with 
permission] 
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1.3.4 Transitional junctions 
 
The transitional junction (TrJ) was first described by Bennett et al. (2006). It was 
observed that titin filaments do not enter the ICD, but terminate in a region just before 
it. This region was thus named the transitional junction (Bennett et al., 2006). Many 
Z-disc proteins are expressed in the TrJ, including α-actinin linked to α-actin (Bennett 
et al., 2006). TrJ junctions are also known to contain N-RAP and ZASP (Bennett et 
al., 2006).  
It has been reported that areas that once contained transitional junctions become 
replaced by sarcomeres containing mature Z-discs and A-bands (Bennett et al., 2006; 
Wilson et al. 2014). This finding led the groups to conclude that the TrJ contributes to 
Z-disc formation. Interestingly, small obscurin isoforms have been reported at the TrJ 
(Ackermann et al., 2012), however further experimental analysis is required to 
confirm this report.  
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1.4 Human Heart Failure 
1.4.1 Definition of heart failure 
Heart failure (HF) occurs either when the heart is unable to effectively fill with blood, 
or to generate sufficient systemic circulation to meet the oxygen demands of the body 
(McMurray et al., 2012).  
A patient with HF typically presents with: (i) Shortness of breath either during 
physical activity or at rest; (ii) Fluid build-up in the pulmonary circulation; and (iii) 
signs of damage to the heart both at macroscopic and microscopic levels. The 
development of HF can be due to either genetic factors (mutations), and/or 
environmental factors. For example, Ischaemic heart disease (coronary heart disease), 
the most common cause of heart failure, results from a combination of genetic factors 
and other risk factors such as hypertension, smoking, hyperlipidaemia, and diabetes 
(The Expert Panel, 1988).   
It is well known that HF increases with age (Go et al., 2014). Approximately 23 
million people are affected worldwide by cardiovascular disease, and approximately 
40% of HF patients do not survive the first year of hospitalisation (Liu and Eisen, 
2014). This results in high economic costs for national health systems (Liao et al., 
2007).  
1.4.2 Systolic and diastolic heart failure 
In diastolic heart failure (DHF), the LV ejection fraction (LVEF) is largely 
unaffected, remaining at healthy levels of 45-65%. LVEF is the fraction of blood 
volume ejected during systole. In systolic failure, the force of ventricular contraction 
decreases significantly. The inability of the ventricles to pump blood (systolic 
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dysfunction), results in a decreased LVEF (<40%). The New York Heart Association 
(NYHA) classification system categorises patients into four classes, depending on the 
severity of the symptoms. The four classes and their corresponding symptoms are 
presented in Table 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3 Pathophysiology of dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is characterised by enlargement of all four chambers 
of the heart (Figure 1.7B) but particularly the left side of the heart, eventually 
resulting in systolic dysfunction. In particular, the walls of the LV become stretched 
and appear thinner (Figure 1.7B), due to both damage and loss of CMs. 
CLASS STAGE SYMPTOMS 
I Risk of developing HF Coronary artery disease, Heart 
disease, Diabetes, Hypertension, 
Obesity, No limitation in physical 
activity 
II Asymptomatic HF Asymptomatic valvular disease, 
LV systolic dysfunction, Previous 
myocardial infarction 
III Symptomatic HF Fatigue, Shortness of breath, 
Reduced tolerance to exercise, 
Evidence of structural heart 
disease 
IV Refractory end-stage 
HF 
Symptoms present at rest even 
after maximum medical treatment 
Table 1.1 The NYHA classification of the severity of HF based on 
physical activity and the presenting symptoms. 
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The damage affects contraction, but relaxation is largely unaltered. Since the stroke 
volume (volume of blood ejected with each beat) decreases, LVEF levels drop below 
~40%. Hence, DCM is classified as a form of systolic heart failure. The congenital 
form of DCM, Familial Dilated Cardiomyopathy (FDCM), is commonly caused by 
mutations in sarcomeric and cytoskeletal protein genes, particularly in the titin (TTN) 
gene (Herman et al., 2012). 
Figure 1.7 Comparison of donor and failing human DCM hearts. (A) Donor 
heart. Tissue samples from donor hearts were taken from the left ventricular free 
wall, outlined by the dashed red line. (B) This image illustrates the overall 
dilatation of the chambers. The thickness of the ventricular walls remains the 
same despite the enlargement of the ventricles. In addition, the loss of 
cardiomyocytes results in the formation of non-elastic fibrotic tissue. 
[Photographs obtained from Seidman and Seidman, 2001, with permission] 
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1.4.4 Histopathology of dilated cardiomyopathy 
In DCM, the LV is significantly enlarged. At the cellular level there is loss of and/or 
reduced branching of cardiomyocytes, which are more commonly multinucleated. 
Some cardiomyocytes undergo cell death and are replaced by collagen and fibrous 
scar tissue (Figure 1.8C, black arrows). The extent of damage to the heart cells varies. 
For instance, some cardiomyocytes are hypertrophied (especially in the early stage of 
DCM), while others appear longer and thinner (late stage of DCM).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 H&E stains from human donor and DCM hearts (A) Section of a healthy 
human heart. Cardiomyocytes are branched (encircled region), and arranged neatly in 
parallel (B) Section of a human DCM heart, showing disarray of cardiomyocytes. The 
separation (dashed outlines) of myocytes occurs as a result of cellular atrophy. (C) Section 
of a human DCM heart. Here, the presence of interstitial fibrosis is significant (black 
arrows). [Image A taken on an Olympus/MBF Stereo Investigator Transmitted Light 
Microscope, at 40x (NA 0.75) objective]  [Images B & C from Radu et al., 2012, with 
permission] 
B C 
A 
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1.5 Giant Myofibrillar Proteins 
The giant myofibrillar proteins comprise a family of striated muscle proteins that 
include titin (~3600 kDa), obscurin (~720-870 kDa), and nebulin (~700-900 kDa).   
1.5.1 Titin 
Titin was originally named connectin by Maruyama and his colleagues (Maruyama et 
al., 1977). However over time, it became more widely known as titin (Wang et al., 
1979). Titin is the largest known protein. It is an elastic protein with viscoelastic 
properties (Maruyama et al., 1977).  The ability of titin to extend and re-fold like a 
„spring‟ is attributable to three significant parts; the PEVK region, the Ig-domains, 
and the N2-B region (Linke et al., 1999). The N2-B isoform is also important to the 
stability of the thin filament, as overexpression of N2-B affects this stability (Linke et 
al., 1999).   
Titin therefore functions as a molecular “spring”, and contributes to the structural 
stability of the sarcomere (Granzier and Labeit, 2006). Titin isoforms thus regulate 
the stiffness of the sarcomere - and hence the stiffness of the heart (Tskhovrebova et 
al., 1997).  
1.5.2 Nebulin 
Nebulin is a sarcomeric protein located within the I-band (Horowits 1986). It contains 
a number of actin-binding domains, and spans the length of actin thin filaments 
(Trinick 1992). By interacting with actin filaments, nebulin is able to regulate their 
length (Keller 1995).  
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1.5.3 Obscurins 
Obscurin is the third largest, and most recently discovered giant myofibrillar protein. 
It is also known as obscurin-Rho guanine nucleotide exchange factor (Obscurin-
RhoGEF), or obscurin-myosin light chain kinase (obscurin-MLCK). It is closely 
related to the nematode muscle M-line protein, UNC-89 (Sutter et al., 2005), and was 
identified via a yeast two-hybrid (Y2H) screen to be a binding partner of titin (Young 
et al., 2001). The obscurin gene (OBSCN) contains 119 exons, which give rise to a 
subfamily of obscurin isoforms (Figure 1.9) arising from multiple spliced domains 
(Fukuzawa et al., 2005).  
The two main large isoforms of obscurin are obscurin A (~720 kDa) and obscurin B 
(~870 kDa). The obscurins were recently reported to be directly implicated in 
sarcomere contraction (Marston et al., 2015). Obscurins play significant roles in 
myofibrillogenesis and contribute to the structural stability and alignment of the 
sarcomere in both mature and developing cardiomyocytes (Borisov et al., 2004).   
In the heart, obscurin A and B bind directly to at least 12 other proteins that in turn 
interact with other proteins. Therefore, obscurin is well positioned and may well 
significantly influence the structure and function of the sarcomere in both donor and 
failing hearts.  
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Figure 1.9 Obscurin isoforms identified or proposed to be expressed in 
humans [Protein information obtained from the UniProt database].   
Panel A illustrates the domain structures of obscurin A (~720 kDa) and B (~870 
kDa). Protein interactions with obscurin A (UniProt code: Q5VST9-3) are 
indicated by the labelled boxes and discussed in detail in the text.  Obscurin B 
(Q5VST9) interacts with the same domains as obscurin A except at its C 
terminal region, which lacks the ankyrin-binding motif and instead has two 
kinase domains with their labelled binding partners. A key to the domains is 
provided in the boxed panel.  
Panel B shows a number of splice isoforms of obscurin: obscurin B (973 kDa, 
A6NGQ3) and obscurin B (973 kDa, H3BPX2), both of which occur at the 
transcript level but are yet to be identified at the protein level. Obscurin B 
isoforms also include: a putative 924 kDa protein (Q5VST9-6); a putative 427 
kDa protein (Q5VST9-5); and a putative 212 kDa protein (A9NIU4). These 
predicted isoforms have not yet been reviewed by UniProt. They share some of 
the same signalling domains present in obscurin A and obscurin B, and so may 
serve analogous roles.  
Panel C describes three additional obscurin isoforms: obscurin (175 kDa, 
H3BQA7), obscurin (94 kDa, A0A0A0MRI8), and obscurin (7 kDa, H3BPW6). 
They consist of only Ig domains. They have no known function.  
Panel D presents two small kinase isoforms, one with a partial SK2 kinase 
domain (with a half bracket) and one with a full SK1 domain. The single kinase 
isoform contains a full SK1 domain, which also interacts with the Na
+
/K
+
-
ATPase channel. The SK2 domain interacts with N-cadherin. These isoforms 
were not listed on UniProt during a recent search, however they have been 
documented in the literature (Hu and Kontrogianni-Konstantopoulos, 2013) and 
potentially can be recognised by the antibody directed against the 4
th
 FnIII 
domain seen in obscurin B. Note: The isoforms in this figure are listed on 
UniProt as of the 3rd of January 2016 but are subject to change. A key to the 
seven functional domains is provided at the bottom of the figure.  
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Obscurin A (~720 kDa) (Fig. 1.9, panel A) has an N -terminal structure comprised of 62 
immunoglobulin-like (Ig) domains, the first three of which bind to myomesin, the C-terminus 
of titin at the M-line, and select variants of slow skeletal MyBP-C (Fukuzawa et al., 2008, 
Ackermann et al., 2009). The series of Ig domains is interrupted by the presence of three 
Fibronectin type-III (FnIII) domains (Perry et al., 2013) (Figure 1.9, panel A).  
The C-terminal regions of obscurin A contain a number of functional domains including (i) a 
calcium-calmodulin (IQ) motif (ii) a Src homology3 (SH3) domain (iii) a Rho Guanine 
nucleotide Exchange Factor (RhoGEF) domain, and (iv) single pleckstrin homology (PH) 
domain. These signalling motifs are followed by a ~400 amino acids long non-modular 
segment that electrostatically binds ankyrins (Busby et al., 2011).  
Obscurin B (~870 kDa) is about 150 kDa larger than obscurin A (Figure 1.9, panel A) and 
has a similar N-terminal Ig/FnIII structure and signalling motifs to obscurin A. However, its 
C-terminus lacks the ankyrin-binding domain and instead contains two serine-threonine 
kinase domains, SK2 and SK1, with the latter preceded by a 4th FnIII domain (Hu and 
Kontrogianni-Konstantopoulos, 2013).   
Obscurins are known to be involved in myofibrillogenesis and molecular signalling between 
the myofilaments, the cytoskeleton, and the sarcoplasmic reticulum (SR) (Borisov et al., 
2004; Borisov et al., 2006; Borisov et al., 2008; Kontrogianni-Konstantopoulos et al., 2003; 
Kontrogianni-Konstantopoulos et al., 2004; Kontrogianni-Konstantopoulos et al., 2009). The 
presence of an IQ motif (Figure 1.9A) and a RhoGEF domain at the C-terminus suggests they 
may be involved in Ca
2+
-calmodulin and small G-protein mediated signalling pathways, both 
of which are vital for myofibril assembly and maintenance (Young et al., 2001). Specifically, 
the Rho-GEF domain (Figure 1.9A) binds TC10 (not shown in Figure 1.9A), a member of the 
small GTP-binding protein family in human skeletal myotubes (Coisy-Quivy et al., 2009).  
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TC10 is also expressed at high levels in the heart (Abe et al., 2003) but it remains to be seen 
whether an interaction occurs between TC10 and Rho-GEF. If so, it may play a key role 
during myofibrillogenesis.  
The obscurin Rho-GEF domain contains a proline-rich sequence, which has been postulated 
as a binding site for SH3 domains (Young et al., 2001). Although this is yet to be proven 
biochemically, it is of great interest, since it would allow obscurin to form homo- or hetero-
dimers or even multimers. The Rho-GEF domains of obscurin A and B in skeletal muscle are 
also reported to bind selectively to RhoA (Ford-Speelman et al., 2009), a small RhoGTPase 
protein that plays a regulatory role in the contraction of the actomyosin lattice (Wheeler et 
al., 2004). The Rho-GEF domain is known to regulate the activity of RhoGTPase proteins, 
which may include RhoA, but this has not yet been shown in cardiac tissue (Russell et al., 
2002). Furthermore, RhoA is one of many key mediators of cardiac hypertrophy (Laufs et al., 
2002), and so the discovery of a RhoGEF-RhoA interaction in the heart would confer a 
regulatory role of obscurin during cardiac hypertrophy.   
Obscurins A and B both carry an SPXR motif in their ~400 amino acids long non-modular C-
terminus (Young et al., 2001). This motif is homologous to the N-terminal XSPXR 
phosphorylation motif present in the Zis-1 and Zis-5 repeats of titin (Young et al., 2001). 
Interestingly, both SPXR/XSPXR motifs of obscurin are probably phosphorylated by the 
proline-directed protein Extracellular Signalling Kinase (ERK) (Young et al., 2001; 
Sebestyen et al., 1995; Voelkel and Linke 2011). XSPXR in cardiac titin is phosphorylated 
by ERK1 and regulates myofibrillogenesis (Sebestyen et al., 1995). Bang et al. (2001) 
reported that the C-terminal region of obscurin which contains the SPXR motif, binds to 
novex-3, a short isoform of titin located in the same region of the sarcomere. It is therefore 
possible that obscurin A and B are also phosphorylated by ERK. Given that the Zis-1 domain 
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of both skeletal and cardiac muscle titins are located at or near the Z disk and are associated 
with I band thin filament proteins such as alpha-actinin and filamin (Labeit et al., 2006), it is 
possible that the C-terminal region of obscurin also binds to these proteins. However, it 
remains to be seen whether phosphorylation regulates this binding.  
The small kinase isoforms (Figure 1.9, panel D) include the tandem kinase (~120 kDa) 
containing partial serine/threonine kinase 2 (SK2) and full-length serine/threonine kinase 1 
(SK1) domains; and the single kinase (~70 kDa) isoform that only contains SK1. Both SK2 
and SK1 are enzymatically active. They undergo auto-phosphorylation, which is thought to 
be vital to their activation (Hu and Kontrogianni-Konstantopoulos, 2013). They belong to the 
myosin light chain kinase family (Russell et al., 2002) implicated in cardiac contractility and 
sarcomere organization (Chan et al., 2008; Seguchi et al., 2007).  
SK2 directly binds and phosphorylates the cytoplasmic domain of N-cadherin at the ICD, and 
therefore may regulate the activity of N-cadherin, a key player in cardiomyocyte adhesion 
(Hu and Kontrogianni-Konstantopoulos, 2013). The SK1 domain directly interacts with the 
β1-subunit of the Na+/K+-ATPase pump, however it is still unknown whether the latter is also 
a substrate besides a ligand of SK1 (Hu and Kontrogianni-Konstantopoulos, 2013). 
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1.5.3.1 Location and expression of obscurin in cardiomyocytes 
During embryonic development (day 12), both obscurin A and B and the smaller kinase 
isoforms are detected in the ventricles of mouse hearts at the transcript level (Borisov et al., 
2008). Whole mount in situ hybridisation has also revealed that the expression of smaller 
kinase isoforms is dominant compared to the larger isoforms during development (Borisov et 
al., 2008). In adult hearts, the mRNA levels of smaller kinase isoforms have been found to be 
50-fold higher than that of the larger obscurin isoforms (Borisov et al., 2008; Nagase et al., 
2000). In another study, the expression of obscurin A was higher in rat cardiac tissue, than in 
skeletal muscle (Lange et al., 2009).  
In contrast, the level of expression of obscurin B is lower in cardiac muscle than in skeletal 
muscle (Russel et al., 2001; Hu and Kontrogianni-Konstantopoulos 2013). In the adult 
mammalian heart, antibodies to the N-terminal Ig domains of obscurin bind to the M-line in 
cardiac sarcomeres (Lange et al., 2009), specifically to the C-terminal M10 Ig domain of titin 
and to My4-My5 of myomesin (Fukuzawa et al., 2008). Using anti-obscurin antibodies, 
Lange et al. (2009) confirmed that obscurin isoforms containing the IQ-Ig64 and Ig66/67 
domains localise to the M-line.   
An immunohistochemical study by Carlsson et al. (2008) used antibodies against the IQ 
domain and the Ob48/49 domains of obscurin. These domains are present in obscurin A and 
B (near their C-termini). Both antibodies stained the periphery of the myobrils at the level of 
the M line, but not the Z-disc (Carlsson et al. 2008). This finding contrasts with a study by 
Bang et al. who found that the C-terminus of obscurin (Ig48/Ig49) binds to novex-3, a short 
isoform of titin located near the Z-disc (Bang et al., 2001). Young et al. observed similar 
results, using anti-obscurin antibodies directed against the IQ domain and Ob48/49 domains 
(Young et al., 2001).  
Chapter 1. Introduction 
26 
 
Table 1.2. Published immunofluorescence work in determining the location of obscurin in 
the cardiac sarcomere. 
 
In summary, the N-terminus of obscurin is localized at the periphery of the myofibril at the 
M-line level, but there is less certainty over whether it surrounds the myofibril at the level of 
the Z disc (Kontrogianni-Konstantopoulos et al., 2003). By comparison in the neonatal heart, 
obscurin is likely to play a role in organizing the A band. It is abundant early in 
embryogenesis, and in neonates it is found at the M-line, before myosin aligns into definitive 
A-bands (Kontrogianni-Konstantopoulos et al., 2004). The M-line in this study was 
recognised by double immunofluorescence staining with α-actinin. This is consistent with the 
Epitope targeted by 
antibody 
Location and isoforms targeted 
 Ig1/2 domains               
(Lange et al., 2009) 
- Localised to the M-line 
- Targeted Obscurin A and B 
IQ-Ig64 and Ig66/67 
(Lange et al., 2009) 
- Localised to the M-line 
- Targeted Obscurin A and B 
IQ domain and Ig48/49 
(Carlsson et al., 2008) 
- Localised to the M-line 
- Targeted Obscurin A and B 
IQ domain and Ig48/49    
(Bang et al., 2001; Young et 
al., 2001) 
- Localised to the Z-disc 
- Targeted Obscurin A and B 
Ig69/FnIII70 and FnIII70 
(Hu and Kontrogianni-
Konstantopoulos 2013) 
- Localised to the Z-disc, M-line, sarcolemma, and ICD 
-Targeted Obscurin A and B, and small kinase isoforms (70 
and 120kDa) 
- Exact subcellular locations of specific isoforms still unknown 
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findings of Borisov et al., who showed that obscurin is needed for the lateral alignment of the 
myofibrils (Borisov et al., 2006).  
  
Figure 1.10 The functions of obscurin isoforms in cardiomyocytes. The major functions 
include phosphorylation, myofibrillar proteins, cell signalling, hypertrophy, interaction with 
intracellular membranes, and heart failure. The boxes arising from these major functions 
outline their secondary functions. There is increasing evidence for a role of obscurin in heart 
failure. The details of how it performs these functions are discussed in the adjacent text. 
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1.5.3.2 Interactions of obscurin with sarcomeric proteins  
Obscurin interacts with both the C-terminus of titin, and the M-line protein myomesin, in 
what is known as a multi-molecular complex (Pernigo et al., 2010). Fukuzawa et al. (2008) 
demonstrated that down regulation of myomesin by siRNA disrupts the integration of 
obscurin into the M-line in neonatal cardiomyocytes. In addition, mutations at the C-terminus 
of titin alter its affinity for obscurin, resulting in the relocation of obscurin away from the M-
line (Fukuzawa et al., 2008).  These authors also found that when myomesin is ablated, 
obscurin remains localised in the Z-disc but not at the M line. This suggests that obscurin 
remains anchored to the sarcomere by its C-terminus, perhaps by titin or its shorter isoforms 
e.g. novex-3. This suggestion is relevant to the data to be presented in this thesis. 
Further towards the C-terminus, the Ig48/49 domains of obscurin present a second interaction 
site with the N-terminal region of titin (Z9-10 domains), at the Z-disc (Young et al., 2001). 
Furthermore, an alternative way for titin and obscurin to interact is via signalling systems, i.e. 
the Rho-GEF domain. The transfer of intracellular (regulatory) signals between the Rho-GEF 
domain (described above) and titin (the stress sensor of cardiomyocytes) may be an important 
collaborative process that enables the myofibril to respond to the stresses that lead to 
hypertrophy.  
Obscurin A, through its unique ankyrin-binding domains at its C-terminal end, interacts with 
ankyrin B. This interaction occurs with different binding affinities (Borisov et al., 2004; 
Kontrogianni-Konstantopoulos et al., 2004; Kontrogianni-Konstantopoulos et al., 2003; 
Kontrogianni-Konstantopoulos et al., 2006). Ankyrin-B (~434 kDa) interacts with the 
ankyrin-binding domain of obscurin A (Cunha and Mohler 2008) (Figure 1.9A). Two 
regulatory domain motifs in ankyrin B necessary for binding to obscurin are located on exon 
43 of the ANK2 gene (Cunha and Mohler 2008). The ankyrin B isoform (specifically exon 
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43‟) is dominantly expressed in both mouse and human heart, and the obscurin-ankyrin B 
interaction is necessary to target ankyrin-B to the M-line (Cunha and Mohler, 2008). Further 
studies using immunofluorescence microscopy confirmed that obscurin and ankyrin-B co-
localise at the M-line in neonatal and adult human cardiomyocytes (Cunha and Mohler, 
2008). When ankyrin exon 43‟ (the obscurin-binding site) is deleted, there is no localisation 
of ankyrin-B to the cardiac M-line (Cunha and Mohler, 2008). Finally, knockout of ankyrin-B 
in neonatal cardiomyocytes did not affect the expression or localisation of obscurin A, 
suggesting that obscurin is independent of ankyrin-B (Cunha and Mohler, 2008). 
Interestingly, obscurin is a significant binding partner of small ankyrin 1 (sAnk1) in skeletal 
muscle (Kontrogianni-Konstantopoulos et al., 2003). This report demonstrates that the 
sarcomere and sarcoplasmic reticulum are linked, via the obscurin - sAnk1 interaction. 
However, this interaction is yet to be confirmed in heart muscle, and thus is not shown in 
Figure 1.9. 
Obscurin interacts with calmodulin (Young et al., 2001). The calmodulin-binding sequence 
includes putative receptors for Ca
2+
 signals, and so may play a major role in the regulation of 
cardiac homeostasis (Stevens 1983). Binding of both obscurins A and B to calmodulin is 
mediated by the IQ motif (Figure 1.9A) located just before Ig52 domain (Young et al., 2001). 
Binding occurs both in the presence and absence of Ca
2+
, suggesting that the obscurin-
calmodulin interaction occurs in a Ca
2+
-independent way (Young et al., 2001). This is 
consistent with the findings of Rhoads and Friedberg (1997), which showed that IQ domains 
bind to calmodulin both in the presence and absence of Ca
2+
. Although this interaction is 
Ca
2+
insensitive, Young et al. (2001) suggested that once-bound calmodulin may act as a 
calcium sensor. In the myocardium, four calmodulins interact with the sarcoplasmic 
reticulum (SR) ryanodine receptor 2 (RyR2) tetramer (Balshaw et al., 2001), and this 
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interaction may be important in heart failure (Maier and Bers, 2007). This suggests that the 
obscurin-calmodulin interaction provides a link between the cardiac sarcomere and the SR. 
This is an unusual function for a sarcomeric protein.  
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Figure 1.11. The location of obscurin isoforms (obscurin A and B, and the kinase isoforms) 
within the different cellular compartments of the cardiomyocyte. The sarcomere has been 
enlarged in this schematic, to illustrate the location of obscurin within the context of the entire cell. 
The thin filaments (red) anchor into the ICD (aqua blue region of membrane). The titin filaments 
(blue) run the length of each half-sarcomere. In this schematic, titin filaments have only been 
included in one half sarcomere, for simplification. The N and C-terminal ends of titin interact with 
obscurin A and B. The N-terminal domains of titin (Z9-10) interact with the Ig48/49 domains of 
obscurin A/B. The C-terminal domain of titin (M10) binds to the Ig1/2 domains of obscurin A/B, 
and to myomesin - forming a ternary complex at the M-line (black outline).  
The N-terminal of obscurin A is found at the M-line, and was identified by many including 
Kontrogianni-Konstantopoulos et al., 2003, Marston et al., 2015 and Lange et al., 2009. Obscurin A, 
through its ankyrin-binding domain, interacts with ankyrin-B. This interaction is essential to 
recruiting ankyrin-B to the M-line. The Ig48/49 domains of obscurin A/B also interact with the titin 
isoform novex-3. This interaction occurs in the I-band. The IQ domain, present in both obscurin A 
and B, binds to calmodulin in the sarcoplasmic reticulum (SR). The obscurin-calmodulin interaction 
provides a direct link between the sarcomere and the SR. Obscurin isoforms bearing the SK1 domain 
bind to Na
+
/K
+
 ATPase (NKAβ1) channels present in both the intercalated disc (ICD) and 
sarcolemma. Obscurin isoforms bearing the SK2 domain bind to N-cadherin, which is present in the 
ICD and the sarcolemma. Obscurin isoforms containing the fourth FnIII domain are found to localise 
to the nucleus of cardiomyocytes. 
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1.5.3.3 The role of obscurin in heart failure 
Obscurins A and B described above take part in an array of cellular interactions in the cardiac 
sarcomere, and disruption of their signalling domains may lead to disease states in the heart. 
Specific deletion of the RhoGEF motif from obscurin A in zebrafish embryos, for example, 
resulted in a number of affects: (i) Cardiac hypoplasia in 54% of embryos (ii) An overall 
decrease in heart rate (iii) Abnormal formation of the ICD  (iv) Disorganized sarcomeric 
filaments; and (v) Reducing the number of myofibrils (Raeker et al., 2010).   
Modification of exon 1 of the OBSCN gene results in complete loss of obscurin A and B at 
the mRNA level, however the mRNA levels of the kinase domains are still present at lower 
levels; suggesting that small kinase isoforms may be expressed independently (Lange et al., 
2009).  
In hypertrophic cardiomyopathy (HCM), two mutations of obscurin were identified in one 
patient. Arg4344Gln in Ig58, and Ala4484Thr in Ig59 located just N-terminal to the IQ 
domain (Arimura et al., 2007). The former but not the latter significantly decreased binding 
of obscurin to the N-terminal Z9-Z10 domains of titin at the Z/I junction, and impaired the 
ability of obscurin to localize at the Z-disc (Arimura et al., 2007). Proof that obscurin is 
pathogenic requires more research. More extensive screening of HCM genotypes is needed 
and mutations in major sarcomeric genes known to cause HCM must be excluded (Van Dijk 
et al., 2012).  
Models of HCM were studied in mouse hearts. After experimental aortic constriction, the 
mRNA transcript levels of the obscurin Rho-GEF and SK2 domains were significantly higher 
compared to donors, over an eight-week interval (Borisov et al., 2003). However, after this 
period, their transcript levels did not significantly differ from donor mice. This suggests their 
upregulation seems to be associated only with the early stages of cardiac hypertrophy 
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(Borisov et al., 2003).  These findings highlight the possibility that the up-regulation of the 
Rho-GEF and SK2 domains are a protective response in the early stages of heart failure.  
Recent evidence has shown that truncated forms of obscurin do in fact integrate to their 
expected locations in the cardiac sarcomere. However partial knockout mice containing 
truncated Ig58/59 domains develop cardiac hypertrophy after 12 months (Hu and 
Kontrogianni-Konstantopoulos, 2013). Similarly, aortic constriction in two-month partial 
knockout mice results in severe hypertrophy, decreased ejection fractions, and functional 
defects (Hu Kontrogianni-Konstantopoulos, 2013).  
Others (Makarenko et al., 2004) analysed titin and obscurin expression in LV samples from 
non-failing human donors and from severely failing (but non-ischemic) DCM transplant 
patients. In non-failing donor hearts, gel electrophoresis and immunoblotting revealed 
obscurin as a strong band at ~900 kDa and a weaker second band at a slightly lower 
molecular weight. In DCM hearts (n = 4), the lower band was generally stronger than the 
upper band, suggesting that there is an isoform switch during disease. Furthermore, their 
immunohistochemistry results reveal a significant loss of myocyte area in these DCM hearts 
(Makarenko et al., 2004). Small kinase isoforms of obscurin may also play a role in disease 
since they localise in the ICD (Ackermann et al., 2012). Hence down regulation of these 
isoforms is likely to disrupt normal ICD function.  
A recent report (Herman et al., 2012) showed that truncating mutations in titin are 
responsible for about 25% of familial dilated cardiomyopathy patients (FDCM). In 
collaboration with the Sydney Heart Bank, whole exome sequencing revealed that 5 of 30 
FDCM patients had a mutation in obscurin. Pyrosequencing revealed that four of the five 
FDCM patients contained an obscurin point mutation, which caused significant down 
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regulation in the large obscurin isoforms A and B (Marston et al., 2015).  Thus, site-directed 
mutations in obscurin may (like the truncating mutation in titin) play a role in FDCM. 
1.6 Aims of This Thesis 
This thesis will examine the expression of obscurin and its small kinase isoforms, whose 
roles are less known. It will determine whether the small kinase isoforms are down regulated 
in FDCM patients carrying a point mutation in the OBSCN gene. This will be done by 
quantifying the amount of fluorescence between mutants and their age-matched donors.  
Since these mutations are likely to affect only a sub-population of obscurin protein isoforms, 
traditional PAGE gel analysis is not informative of obscurins at particular sub-cellular 
locations. Immunohistochemistry can monitor levels of mutant obscurin at different locations 
in cardiomyocytes while gels only provide an overall measurement of protein levels. 
Nevertheless, it would be useful in determining the size and relative quantities of isoforms 
detected by the antibodies.  
Access to these samples through the Sydney Heart Bank has been crucial. Two of the FDCM 
patients LV samples were collected very early in the history of the Bank and were fully 
consumed by earlier projects, leaving only two hearts available for comparison with healthy 
donors. One of these was an error of the NGS discovered very late in the duration of research 
for this thesis. This sequencing error provided a positive “control” since we expected but did 
not observe changes in obscurin levels. Despite this, the research described here presents 
several milestones in the obscurin field because it is entirely based on human failing and non-
failing hearts. It therefore builds on and is largely consistent with a substantial animal model 
literature.  
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2.1. Collection of heart samples 
 
2.1.1.    Ethics 
Human Research Ethics Committee (HREC) approvals were granted from St Vincent‟s 
Hospital (#H91/048/1a) for the collection of tissue from orthotopic transplant patients and 
from the University of Sydney HREC (#12146) to permit experimental work on the tissue, 
carried out on campus. These approvals were subject to the submission of annual reports 
covering issues such as unforseen incidents, injuries and changes in personnel.  
2.1.2      Collection and storage of heart tissue 
Heart samples were collected from patients with end-stage heart failure or from healthy donor 
hearts that were not suitable for transplantation. Samples were stored in cryovials in liquid 
nitrogen (-196ºC) in the Sydney Heart Bank (Director Professor Cris dos Remedios; Curator 
Dr Sean Lal). This bank follows strict guidelines of use and collection to prevent protein and 
RNA degradation.  
2.1.2.1   Donor hearts 
The collection of donor hearts was comprised of hearts from heart transplant recipients, organ 
donors for which there were no tissue matched recipients, dead body organ donors and other 
sources such as other heart tissue banks. Within a few minutes of cross clamping (stopping 
the coronary circulation), donor hearts were perfused with ice-cold cardioplegic solution.  
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2.1.2.2    End-stage failing hearts 
End-stage failing hearts were obtained from patients receiving a heart transplant. For those 
patients under the age of 55 years, the aortic and pulmonary valves were harvested by the 
Sydney Valve Clinic. Some tissue was reserved for the St Vincent‟s Hospital Department of 
Anatomical Pathology. In most cases, approximately 50% of the heart tissue was obtained for 
experimentation.  
2.1.2.3    Dissecting and cataloguing heart tissue 
Once the heart tissue was received, each chamber of the heart was dissected into smaller 
trans-mural samples, approximately one gram each. First, the LV was dissected into strips 
starting from the anterior wall and gradually moving towards the posterior free wall. Each 
strip was sectioned into smaller samples and numbered from the base (e.g. LV1) to the apex 
(e.g. LV8-9).  
Each sample was labelled with a four-digit patient code that bore no relation to the patient‟s 
medical record number or date of birth. This served the purpose of de-identifying the patient. 
For patient samples collected prior to 2003, this rule does not apply, as it is not feasible to 
remove earlier identifiers or replace them.  
2.1.2.4    Heart failure patients and donors 
This thesis focused on FDCM patients with a known mutation in obscurin. Next generation 
sequencing (NGS) revealed 5 FDCM patients with a mutation in the obscurin gene (OBSCN). 
Three of these patients (3.070, 1.041 & 1.059) were not analysed, as their LV samples were 
exhausted. One of the 5 patients (4.121) was initially identified as having a truncating 
mutation (p.A998G fs*85). However this was revealed to be an error after verification with 
pyrosequencing. This sample was initially included in the obscurin mutation group, as the 
error was not known at the time of the experiment. Age-matched donors were chosen as 
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“donor” subjects. The donor samples listed in Table 2.1 were also used for localisation 
studies. Sequencing analysis was performed by Ralph Knoll and Marston et al., 2015. Details 
pertaining to NGS and pyrosequencing can be found in the supplementary material of 
Marston et al., 2015. The sequencing error did not need to be put into public data banks.  
 
 
 
Code Collection 
date 
Diagnosis 
S
ex
 
Age Mutation NYHA 
Class 
 CO(L/
min) 
 
Pathology 
Report 
 
4.121 
 
08.06.05 
 
FDCM 
 
F 
 
29 
None 
Initial 
mutation: 
pA998G 
fs*85 
 
 
IV 
 
5 
 
2.7 Viral CM, 
No 
coronary 
disease 
6.038 28.01.10 
 
DONOR 
 
M 
 
25 
 
- 
 
- 
 
- 
 
- 
CV2-3 
fracture 
COD: 
drowned 
7.024 24.06.10 DONOR M 28 
- - - - Posterior 
LV 
ischemia. 
COD: 
Cardiac 
arrest 
2.066 
18.07.94 
FDCM M 43 
OBSCN 
(p.E963K) 
IV 10 - 
No IHD 
6.024 18.01.10 DONOR F 45 
- - - - Grade V 
SAH 
COD: 
Collapsed, 
unresponsi
ve 
6.042 
29.01.10 
DONOR F 44 
- - - - SAH (burst 
BAA) 
COD: 
Cardiac 
arrest 
Table 2.1: Patient data of all samples used for experimental studies. Patient 4.121 was identified by next 
generation sequencing to have a truncating mutation (p.A998G fs*85), however pyrosequencing revealed 
this to be an error. Abbreviations: New York Heart Association (NYHA) Class, Fractional Shortening 
(FS), Cardiac Output (CO), subarachnoid haemorrhage (SAH), and bronchial arterial aneurysm (BAA). 
The Cause of Death (COD) is included for donor samples.  
 
 
 
Code Collection 
date 
Diagnosis 
S
ex
 
Age M tation NYHA 
Class 
F
S
 
( 
CO 
(L/min) 
 
Pathol
ogy 
Report 
 
4.121 
 
0 . 6.05 
 
FDCM 
 
F 
 
29 
No 
mutation 
Initial 
mutation:  
(p.A998Gf
s*85) 
 
 
IV 
 
5 
 
2.7 
Viral 
CM, 
coronary 
a gio 
normal, 
normal 
coronary 
arteries 
6.038 28.01.10 
 
DONOR 
 
M 
 
25 
 
- 
 
- 
 
- 
 
- 
CV2-3 
fracture 
COD: 
drowned 
7. 24 24. 6.10 R M 28 
- - - - Poland 
syndrom
e. 
Posterior 
ischemia. 
COD: 
Cardiac 
arrest 
2.066 
18.07.94 
FDCM M 43 
OBSCN 
(p.E963K) 
IV 10 - 
No IHD 
6.024 18.01.10 DONOR F 45 
- - - - Grade V 
SAH 
COD: 
Collapse
d, 
unrespon
sive 
6.042 
29.01.10 
DONOR F 44 
- - - - SAH 
(burst 
BAA) 
COD: 
Cardiac 
arrest 
FS (%) 
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2.2 Preparation of frozen heart Samples  
LV samples of interest were extracted from the Sydney Heart Bank. The cryovials were 
cracked open with a hammer under liquid nitrogen. The exposed heart tissue was then placed 
in a mortar, cooled with liquid nitrogen and broken into smaller fragments using a pestle. An 
appropriate sized sample of tissue was selected (approximately 4 mm x 4 mm), placed in a 
new labelled cryovial, and stored in crushed dry ice (-80°C) for 2 hours. Samples were 
gradually warmed in dry ice to minimise tissue damage. The remaining tissue was placed into 
new labelled cryovials and returned to the bank.  
2.3 Detection of Obscurin Using Immunofluorescence  
To analyse the localisation and expression of obscurin, LV samples were cryosectioned and 
stained with the appropriate antibodies.  
2.3.1 Sectioning of heart tissue 
The heart sample of interest was moved from dry ice and placed directly into the cryostat 
chamber (Leica CM3050 S). The cryostat temperature (CT) and object temperature (OT) 
were set to -23°C. The cryovials containing the samples were placed in the cryostat chamber 
for approximately 10 minutes before sectioning. Once equilibrated to the new temperature, 
OCT solution was spread evenly across the surface of a clean cryochuck. The tissue was 
immediately placed into the OCT, which then solidified. Once solidified, a small amount of 
OCT was added to the top surface of the tissue block. The cryochuck was secured onto the 
arm, and excess OCT was trimmed until the surface of the tissue appeared. The anti-roll plate 
was then placed above the blade, and 5 µm sections were cut. Once cut, sections were placed 
onto pre-cooled glass slides (Menzel-Gläser SUPERFROST
®
 PLUS), and allowed to 
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gradually adhere within the cryostat chamber.  Slides were then transferred to room 
temperature for staining.  
2.3.2 Antibodies to obscurin 
Two obscurin antibodies were used for immunofluorescence experiments. The first was a 
mouse anti-obscurin antibody targeting Ig1/2 of both obscurin A and B (provided by 
Kontrogianni-Konstantopoulos and used previously in Kontrogianni-Konstantopoulos et al., 
2006). The second was a rabbit anti-obscurin antibody targeting the fourth fibronectin III 
(FnIII) domain. This antibody was provided by Kontrogianni-Konstantopoulos and used 
previously in Hu and Kontrogianni-Konstantopoulos 2013, who identified molecular weight 
bands at 870 kDa, 600kDa, 120 kDa and 70 kDa. (Figure 2.1).   
 
 
Figure 2.1. Location of obscurin antibodies. The mouse antibody targeting Ig1/2 domains, can detect 
both obscurin A and B. The rabbit antibody targeting the fourth fibronectin III domain, can detect both 
obscurin B, and smaller kinase isoforms. The fourth domain is not present in obscurin A; hence this 
antibody cannot detect obscurin A. The isoforms above contain many other domains, which have been 
excluded here for simplification purposes.  
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2.3.3 Antibody staining of cryosections  
Prior to staining, sections were allowed to sit at room temperature for approximately 5 
minutes to ensure complete adhesion to the slide. Then, each section was surrounded by 
vacuum grease (Technical, Asia Pacific Speciality Chemicals). The vacuum grease formed a 
hydrophobic barrier to prevent the leakage and/or mixing of antibody solutions. The sections 
were fixed with ice-cold acetone (Chem-Supply, Gillman, SA) and incubated for 5-7 minutes 
at -20°C. They were then washed in ice-cold PBS (Sigma Aldrich P4417) twice, for 5 
minutes.  Non-specific protein interactions were blocked with 2% BSA (Sigma Aldrich 
A9647) in PBS, and incubated for one hour in a humidified wet chamber. All primary 
antibodies were diluted in 2 ml of 2% BSA/PBS. Table 2.2 lists the dilution factors for all 
primary antibodies. The dilution factors of secondary antibodies were identical to their 
corresponding primary antibodies.  
 
 
 
 
 
  
Type of experiment Dilution factors 
Localisation at the Z-disc FnIII primary (1:500), 
α-actinin 2  (1 in 1000) 
Localisation at the M-line Ig1/2 primary (1:1000), 
α-actinin 4 (1:400) 
Colocalisation at the ICD FnIII primary (1:1000), 
connexin-43 (1:1000) 
Quantification studies FnIII primary (1:1000) 
Perinuclear staining FnIII primary (1:1000) 
Table 2.2 Dilution factors of all primary antibodies used for microscopy 
analysis. Each type of experiment is listed with its corresponding primary antibodies 
and dilutions.  
 
 
Table 2.2 Dilution factors of all primary antibodies used for microscopy 
analysis. Each type of experiment is listed with its corresponding primary 
antibodies and dilutions. The dilution factors used for secondary antibodies 
(not listed), were identical to their corresponding primary antibodies.  
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Primary antibody solutions were then added to each section and incubated in a humidified 
wet chamber overnight at 4°C. Following overnight incubation, excess antibody was removed 
by three 5 minute washes in PBS. Primary antibodies were then detected using the 
appropriate Alexa Fluor® dyes, diluted in 2ml of 2% BSA/PBS, and incubated for 1 hour 
(room temperature). The secondary antibodies used were goat anti-rabbit Alexa Fluor®  488 
(ThermoFisher  #A-11034)  and goat anti-mouse Alexa Fluor®   568 (ThermoFisher # A-
11001). 
After secondary antibody incubation, sections were washed three times in PBS for 5 minutes 
each. Anti-fade mounting medium (ProLong
®
 Gold antifade reagent with DAPI, Molecular 
Probes, Life Technologies) was added, the slides cover-slipped (Menzel-Gläser) and sealed 
with nail polish. Confocal imaging was performed as soon as possible after cover-slipping.  
For double antibody staining of sections, antibodies were diluted together within the same 
solution of 2% BSA/PBS. All other steps were followed as above.  
2.3.4 Confocal microscopy imaging 
2.3.4.1 Localisation studies 
Cryosections of LV tissue were imaged using a Zeiss LSM 510 Meta Confocal Microscope. 
Images were initially scanned at 20x objective (NA 0.8) to select suitable regions for imaging 
at higher magnification. This involved careful selection of areas of the tissue that were 
morphologically intact. After identifying a region of interest, images were taken at a 100x 
(NA 1.40) oil objective, using a drop of immersol oil 
TM
 518F (Zeiss). 
To observe the exact location of the FnIII obscurin antibody, sections were co-stained with α-
actinin 2 (labelled with a Alexa Fluor® 568), which resides in the Z-disk of sarcomeres 
(Frank et al., 2006). Preliminary results from co-labelling experiments showed a possible 
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overlap and hence co-localisation of these two antibodies Therefore, a series of Z-stack 
images were taken at 0.10 µm intervals, to determine more precisely the location of each 
protein within the sarcomere. Z-stacks were taken using an optimal pinhole diameter of 1.00 
Airy Unit, frame size 2048 x 2048 pixels, and following averaging of 8 Z-stacks to improve 
the signal to noise ratio.  
To observe the sarcomere location of the Ig1/2 obscurin antibody, sections were co-stained 
with α-actinin 4 antibody (labelled with Alexa Fluor® 488), which uniquely resides on 
adjacent sides of the Z-disc. In this case, Z-stack imaging was performed at 0.30 µm intervals 
and the Z-stack settings were identical to those above.  
2.3.4.2 Colocalisation at the ICD 
Preliminary results showed that the FnIII obscurin antibody co-localised with connexin-43, a 
common marker of the ICD. The dilution of the obscurin antibody was therefore increased 
from 1 in 500 to 1 in 1000, to better differentiate between obscurin and connexin-4 (labelled 
with a Alexa Fluor® 568). This study was performed using healthy donor tissues.  
Sections were initially imaged at 10x (NA 0.45) resolution to observe any possible 
colocalisation. Then, imaging was done at 20x (NA 0.8) objective and 63x (NA 1.40) 
objective to observe the colocalisation more closely. Bitplane Imaris
®
 software was used to 
calculate Pearson‟s correlation coefficient. This coefficient measures the degree to which two 
fluorophores are correlated to one another, and is not affected by signal background (Dunn et 
al., 2011). Pearson‟s coefficient values were noted, and can be found in Chapter 3.2.  
High magnification Z-stack imaging was performed using both the Zeiss 510 and 800 
confocal microscopes, in order to determine the precise location of obscurin and connexin-43. 
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The Z-stack slices/images were analysed using Bitplane Imaris
®
 3D visualisation software, to 
carry out 3D volume rendering and to create 3D projections. 
2.3.4.3 Measuring the fluorescence intensity of obscurin in the ICD 
Since many mutations have been implicated in cardiomyopathies (discopathies), the 
fluorescence intensity of the FnIII antibody was measured in FDCM patients with a mutation 
in the OBSCN gene. Hence any significant differences in intensity between these patients and 
their donors would provide a measure of protein expression.    
The FnIII antibody of obscurin was immunostained on 5 µm sections at a dilution of 1 in 
1000, which was found to be optimal for ICD imaging. Each obscurin mutant and its age-
matched donors (controls) were stained and imaged within the same experimental run. The 
microscope settings (pinhole diameter, laser power, amplifier offset, and scan times) were 
held constant for all images, both in failing and non-failing tissue sections.  
From each tissue sample, six cryosections were prepared. A total of 10 images were taken for 
each patient and each donor (at 63x magnification). Care was taken to ensure that images 
were obtained from regions of tissue that were both longitudinally orientated and 
morphologically intact.  
After imaging, fluorescence intensity was measured using Metamorph
®
 image analysis 
software.  The fluorescence intensity of obscurin labelling was then measured and compared 
between FDCM patients (with an obscurin mutation) and their age-matched donors. 
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2.4 Image Analysis 
For intensity measurements, each image was first set to a threshold in Metamorph
®
. 
Thresholding selects fluorescent objects for measurement and can be adjusted so that only 
objects of interest are measured by the software. An example of this can be seen in Figure 
2.2, where light objects i.e. those containing green pixels, were selected for measurement. 
They are highlighted in orange.  The threshold range (51-255) was kept constant for all 
images, to maintain consistency. 
 
 
 
  
A 
 
A 
B 
 
B 
Figure 2.2: Confocal image of a 5 µm section (A), and its thresholded image (B).   The section was 
cut from patient 4.121 (a FDCM patient – see Table 2.1), stained with a FnIII anti-obscurin antibody. 
It represents 1 of 10 micrographs from the patient, selected for quantification. After thresholding, the 
image on the right was produced. The threshold cursor was adjusted so as to only select the orange 
objects (ICDs) for intensity measurements. The threshold range (51-255), determined by the position 
of the cursor, was automatically logged into an Excel file. For the purposes of quantifying antibody 
expression in failing and non-failing hearts, the threshold range was kept constant.  
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2.5 Optimisation of the Quantification Protocol 
To control for the variation in the number and size of ICDs across the images, the average 
length and area of ICDs were factored into the measurements. Metamorph
®
 was configured, 
so that the software measured the length and area of each ICD in an image, as well as its 
corresponding fluorescence intensity. It then summed these values, to provide the average 
length and average intensity of ICDs in each image. This was repeated to obtain average area 
and average intensity of ICDs for each image.  
The intensity per unit length values were calculated by dividing intensity by length. The 
intensity per unit area values were obtained by dividing intensity by area.    
It was extremely important to avoid over-saturation of the antibody intensity during confocal 
imaging. The range indicator was used to prevent oversaturation. Furthermore, images were 
taken at a high magnification of 63x (NA 1.40), to minimise the number of non-specific 
objects. If present, they were manually removed with relative ease in Metamorph
®
. Such an 
approach prevented non-specific objects from being included in the measurements, which 
may bias the final statistical outcome. An additional age-matched donor (control) was 
included for each obscurin mutant, to increase the validity of the statistical results.  
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2.6 Statistical Analysis 
Statistical analysis was performed using SPSS (IBM) predictive analysis software. A one-
way analysis of variance (ANOVA) test was implemented, to determine statistical 
significances between putative obscurin mutants and their donors.  
This test controls for increases in errors that may arise if two t-tests were performed for three 
or more groups. The type of Post hoc test to use also depended on whether comparable 
groups had equal or unequal variance. Thus, Levene‟s test was performed, to determine if 
there was equal variance between all groups. If the p-value of this test is not significant, then 
one can assume equal variance between samples.  
Since all comparable groups showed equal variance, a Post Hoc Tukey test was used to 
identify groups that were statistically different. Graphs were plotted using GraphPad Prism
®
. 
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3.1 Connexin-43 and obscurin co-labelling at the ICD 
An anti-obscurin antibody provided by Dr Kontrogianni-Konstantopoulos was incubated on 
cryosections (see Chapter 2) of healthy donor LV that strongly localised to large structures, 
which due to their size and location, were identified as putative intercalated discs. This 
particular antibody is directed against an epitope that is unique to a peptide in the FnIII 
domain which is close to the kinase domain (first used by Hu and Kontrogianni-
Konstantopoulos 2013). To confirm this predicted localisation, cryosections were counter-
stained with a commercial antibody directed against connexin-43, a protein known to be 
expressed in the ICD (Kanter et al., 1992).  
Figure 3.1A is a confocal image of the staining pattern of the anti-connexin-43 antibody 
imaged using an Alexa-568 (red) secondary antibody. Initially, 10x magnification images 
were acquired to provide an overview of the density and labelling intensity of obscurin and 
connexin-43 at the ICD. The dilution factor of the obscurin antibody was optimised for this 
study to 1:1000. Under these conditions sarcomeric staining of obscurin is not evident.  
Figure 3.1B is a confocal image of the obscurin FnIII antibody, seen here as the green label. 
Dual labelling using obscurin and connexin-43 antibodies (Figure 3.1C), revealed both to 
coincide at the ICD. This co-localisation is seen as the yellow colour of the ICDs. The nuclei 
are stained with DAPI (blue). 
Note: All confocal images in this Chapter were taken using a Zeiss LSM 510 Meta Confocal 
microscope. 
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Figure 3.1 10x magnification confocal images demonstrating co-localisation of 
obscurin and connexin-43. Panel A illustrates the location of the connexin-43 
antibody labelled with an Alexa Fluor® 568 secondary antibody. It is a common 
marker of the ICD. (B) Staining of the obscurin antibody targeting the fourth FnIII 
domain, and labelled with an Alexa Fluor® 488 secondary. (C) Colocalisation of 
obscurin and connexin-43 at the ICD, which appears yellow.  
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Higher resolution confocal imaging [20x and 63x oil objectives] was then performed on 
several donor tissues, in order to determine the precise nature of staining of obscurin at the 
ICD. In Figures 3.2 A and B, colocalised areas appear yellow. In these studies, the 
background staining of the tissue was clearly visible (Figure 3.2A); however this was not 
considered an issue, since the focus was made to the ICD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
Figure 3.2 Panel A shows a 20x magnification of a region of Figure 3.1C. Here the anti-
FnIII obscurin antibody (counter-stained with a Alexa 488 secondary antibody) and anti-
connexin-43 (counter-stained with a Alexa 568 secondary antibody) are colocalised 
(yellow). Nuclei are stained with DAPI (blue). (B) Higher magnification (63x) of a region 
within the same tissue section.  
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3.2 Colocalisation analysis obscurin and connexin-43  
To investigate the degree of colocalisation between obscurin and Connexin-43 in the ICD, 
colocalisation analyses were performed using confocal micrographs of co-labelled ICDs. 
Analysis involved the use of three different donors, using Bitplane Imaris
®
. Using this 
software, objects of interest i.e. the ICDs, were selected using the threshold tool (Figure 3.3B, 
white regions of ICDs). The software then computed Pearson‟s coefficients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
Figure 3.3 Colocalisation analysis of obscurin and connexin-43 at the ICD (A) Co-
staining of obscurin and connexin-43, at 63x magnification. (B) Threshold mask (white) 
showing ICDs selected for analysis.  
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For Figure 3.3A, the Pearson‟s coefficient measured 0.73. This value indicates that there was 
73% colocalisation between obscurin (green pixels) and Connexin-43 (red pixels). 
Colocalisation analyses were also done for individual ICDs. This is because the degree of 
correlation is often found to be higher when areas of interest, such as single cells, are only 
considered (Dunn et al., 2011). In Figure 3.4A and B, individual ICDs were selected by 
tracing a white line around them, subsequently creating regions of interest.   
The Pearson‟s coefficient for the ICD in Figure 3.4A was measured to be 0.81, suggesting a 
higher correlation of green and red pixels in individual ICDs. An additional ICD was selected 
for colocalisation analysis (Figure 3.4B). The Pearson‟s correlation coefficient here was 
found to be 0.78.  
Further colocalisation analyses was performed on two additional donor tissues, in order to 
confirm that obscurin colocalises to the ICD in human LV tissue. In Figure 3.5B and C, the 
Pearson‟s correlation coefficient was found to be 0.85 and 0.83 respectively. In another donor 
tissue of Figure 3.6 B and C, Pearson‟s correlation coefficient was measured to be 0.77 and 
0.78, respectively. A 3D projection (Figure 3.6D) was created from Figure 3.6C. This 3D 
image demonstrated the colocalisation of obscurin and connexin-43 from another perspective. 
It is clear that obscurin (green) coincides with connexin-43 (red) at the ICD (white arrow).    
Overall, the high Pearson‟s correlation coefficients obtained for individual ICDs across donor 
tissues, lead to the conclusion that obscurin isoforms (bearing the FnIII domain), reside in the 
ICD of human LV tissue.  
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Figure 3.4 Colocalisation analysis of obscurin and connexin-43 in individual ICDs 
(A) A single ICD, outlined in white, with a Pearson‟s coefficient of 0.81 (B) The 
Pearson‟s correlation coefficient for the ICD, outlined in white,  was found to be 0.78. 
Scale bar: 25μm.  
 
A 
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Figure 3.5 Colocalisation analysis of obscurin in selected ICDs of a second donor tissue 
sample (A) Overall confocal micrograph from a second donor tissue. (B) A single ICD 
analysed, outlined in white, with a Pearson‟s coefficient of 0.85. (C) The ICD outlined in 
white, with a measured Pearson‟s correlation coefficient of 0.83. The confocal micrograph 
above was taken at 63x (NA 1.40) magnification. Scale bar: 10μm.  
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Figure 3.6 Colocalisation analysis of obscurin in a third donor tissue sample (A) 
Confocal micrograph of an LV section from the third donor tissue. (B) A single ICD 
outlined in white, was found to have a Pearson‟s correlation coefficient of 0.77. (C) 
The ICD outlined in white, with a Pearson‟s correlation coefficient of 0.78. (D)A 3D 
projection of Figure C, with obscurin (green) and connexin-43 (red) coinciding in 
the same region – the ICD. The scale bar for this image is 5μm. Confocal 
micrograph taken at 63x (NA 1.40) magnification. 
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3.3 High magnification study of the ICD (Zeiss LSM 800 microscope) 
The ICD, stained with the FnIII obscurin antibody, was analysed using the new Zeiss LSM 
800 Confocal microscope. The 1.7x higher resolution provided by the microscope gave a 
more detailed look into the nature of obscurin staining within the ICD. As seen in Figure 3.7 
below, the staining of the obscurin antibody appeared in a “stack-like” fashion. It is possible 
that these „stacks‟ represent the sloping sides of the folds in the plicate region of the ICD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Zeiss LSM 510 Meta Confocal microscope did not provide the same detail of staining, 
when imaging ICDs at 100x magnification. This is evident with Figure 3.8B, whereby the 
stack-like pattern of staining is not apparent. To illustrate the difference in resolution between 
the two microscopes, plot profiles (Intensity vs. Length) were created. A plot profile was 
Figure 3.7. High magnification (120x) image of the obscurin antibody 
(green) at the cardiac ICD. The obscurin antibody was co-stained with 
α-actinin 2 (red), which localises to the Z-disc. The obscurin antibody 
appears here in a “stack like” fashion.  
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created by drawing a single line longitudinally through the ICD (Figure 3.8A). The plot 
profile Figure 3.8A demonstrates the peaks in fluorescence intensity, which occurs at regular 
intervals. This pattern in the plot profile corresponds to the stack-like distribution of the 
antibody seen in Figure 3.8A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.8 High magnification imaging of the cardiac ICD stained with the FnIII obscurin 
antibody (A) Confocal micrograph showing staining of the FnIII obscurin antibody (green), 
using the Zeiss LSM 800 Confocal microscope. The ICD was scanned as a line through the 
middle as shown, which then produced a plot profile for the ICD, shown beneath Figure 3.8A. 
Each peak of fluorescence intensity corresponds to a „stack‟ in the ICD (B) A micrograph of the 
cardiac ICD imaged at 100x magnification. The plot profile of the selected ICD (encircled 
region) is shown below Figure 3.8B.  
A B 
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3.4 Analysis of obscurin expression in the ICD 
A number of mutations in genes encoding for ICD proteins have resulted in heart failure 
(discopathies). The dominant expression of obscurin isoforms in the ICD opens the 
possibility that obscurin point mutations also contribute to the development of heart failure.  
This question may be answered when more FDCM LV samples can be acquired by the 
Sydney Heart Bank. 
In this study, confocal fluorescence microscopy was used to quantify the expressional levels 
of obscurin in the ICDs of LV tissue from FDCM patients (carrying the OBSCN mutation) 
and donor hearts (age-matched donors). The fluorescence intensities (gray value, AU) of 
ICDs were analysed, to provide an indication of the level of protein present. Thus, any 
significant differences in intensity between FDCM patients and their donors would indicate a 
change in protein levels.  
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3.4.1 Comparative study: Measuring intensity per micron length of ICDs 
3.4.1.1 Using the point mutant 
Laser scanning confocal microscopy of immunolabelled tissue showed localised staining of 
obscurin to the ICDs of cardiomyocytes (Figure 3.1 &3.2). This localisation was further 
confirmed by co-labelling studies using the connexin-43 antibody (see Chapter 3.1). The 
negative control (stained with secondary antibody only) did not show any non-specific or 
background staining (see Appendix A). 
As seen in Figures 3.9-3.11 & 3.13-3.15, the length and width (measurement parameters later 
used to calculate area) of the ICDs varies within and between images. This is likely due to the 
tissue sectioning process, which results in ICDs being cut at different cross-sectional angles. 
Morphometric parameters such as length (µm) and area (μm2), as well as the average 
fluorescence intensity for each image, were measured in Metamorph
®
 and directly logged 
into a Microsoft Excel file. Table 3.1 lists the mean length and mean area of ICDs measured 
by Metamorph
® 
for each confocal image of the point mutant. The corresponding fluorescence 
intensity for each image is also shown. Table 3.2 lists the mean values of length, area, and 
intensity for each image of age-matched donor 1. Table 3.3 lists the mean values of length, 
area, and intensity for each image of age-matched donor 2.  
Using Microsoft Excel, the final average length of ICDs was calculated for the point mutant 
and its age-matched donors. These final averages are highlighted in yellow in Tables 3.1-3.3. 
When comparing the averages of length between the point mutant and age-matched donor 1, 
it was found that there was no significant difference between them (p=0.52). Similarly, when 
comparing the final averages of length between the point mutant and age-matched donor 2, 
no significant difference was found between them (p=0.06). 
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Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 1395252 21 192
B 1354754 22 205
C 1823557 29 228
D 1860128 29 247
E 1509315 23 201
F 1374207 27 186
G 1670848 28 219
H 1890359 22 294
I 1510547 26 216
J 1357654 22 224
Average 25 221
Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 4991511 27 268
B 4424183 25 215
C 4735716 25 253
D 4506762 26 232
E 4327377 24 233
F 4972503 27 285
G 4390307 28 252
H 4393003 24 235
I 4257007 26 247
J 4216259 24 227
Average 26 245
Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 5064270 31 281
B 4206810 22 246
C 4895666 27 281
D 5108649 27 263
E 4517875 30 242
F 4409164 28 237
G 4499328 29 230
H 4259826 25 225
I 4501810 31 235
J 4386580 26 210
Average 28 245
  
Table 3.1 Average length and area values for the point mutant. The final 
calculated average values for length are highlighted in yellow at the bottom of 
the table. The final average value for area is highlighted in blue.  
 
Table 3.2 Average length and area values for age-matched donor 1  
 
Table 3.3 Average length and area values for age-matched donor 2 
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The final average area of ICDs was also calculated for the point mutant and its age-matched 
donors. These final averages are highlighted in blue in Tables 3.1-3.3. The final average area 
of the point mutant was not found to be significantly different from age-matched donor 1 
(p=0.06) or age-matched donor 2 (p=0.07). 
Overall, there were no differences in length or area between the point mutant and its age-
matched donors. Therefore, intensity per unit length values could be calculated and used in 
the final statistical analyses, to quantify the amount of antibody in the point mutant and its 
donors. Furthermore, intensity per unit area values were calculated and used, to confirm the 
findings.  
The intensity per unit length values for the ICDs of the point mutant are listed in Table 3.4. 
The confocal micrographs corresponding to each value of intensity per unit length are 
presented in Figure 3.8.  
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.4 Intensity per unit length values for the point mutant. The values below 
were obtained by dividing the average fluorescence intensity by the average length 
of ICDs, for each image.  
 Image Intensity per length
A 67381
B 61971
C 62881
D 64142
E 65622
F 50897
G 59673
H 85925
I 58098
J 61712
Average 63830
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Figure 3.9 (A-J) Confocal micrographs showing obscurin labelling in a FDCM patient 
with a point mutation in the OBSCN gene (Patient 2.066) The FnIII obscurin antibody 
was labelled with a goat anti-rabbit Alexa Fluor® 488 secondary antibody (green). Note 
that the obscurin antibody localises to the ICDs, some of which are indicated by white 
arrows. All images were taken at a 63x (NA 1.40) oil objective. Scale bar: 20µm.  
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Confocal images of the obscurin antibody-labelled LV from two donors that were age-
matched to the point mutant are shown in Figure 3.10 and 3.11. The fluorescence intensities 
of the ICDs in the donor images are clearly brighter compared to those of the point mutant. 
This is reflected in the average intensity per unit length values for the donors (Table 3.5 and 
3.6). The final average of intensity per unit length for both donor 1 and 2 (176,832 gray 
value units/μm and 167,265 gray value units/μm respectively) are much higher compared 
to that of the point mutant (63,830 gray value units/μm). Final averages of intensity per unit 
length in Tables 3.4, 3.5, and 3.6, were used in the statistical analysis (Chapter 3.4.1.2).  
 
  
Table 3.5 Intensity per unit length values for age-matched donor 1. These 
values were obtained by dividing the average fluorescence intensity of ICDs by 
their average lengths.   
Table 3.6 Intensity per unit length values for age-matched donor 2 
Image Intensity per length
A 184871
B 176967
C 189429
D 173337
E 180307
F 184167
G 156797
H 183042
I 163731
J 175677
Average 176832
Image Intensity per length
A 163364
B 191219
C 181321
D 189209
E 150596
F 157470
G 155149
H 170393
I 145220
J 168715
Average 167265
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Figure 3.10 (A-J) Confocal micrographs from age-matched donor 1 (Patient 6.042). 
The obscurin primary antibody was labelled with a goat anti-rabbit Alexa Fluor® 488 
secondary antibody (green). The antibody, targeting the FnIII domain of obscurin, 
localises to the ICDs of cardiomyocytes as indicated by white arrows.  All images were 
taken at a 63x (NA 1.40) oil objective. Scale bar: 20µm. 
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Figure 3.11 (A-J) Confocal micrographs from age-matched donor 2 (Patient 6.024). 
The green fluorescence labelling represents obscurin FnIII antibody, using indirect 
immunofluorescence and a goat anti-rabbit Alexa Fluor® 488 secondary antibody. Here, 
obscurin is seen to localise to the ICDs of cardiomyocytes (white arrows). The images were 
acquired at a 63x (NA 1.40) oil objective. Scale bar: 20μm. 
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3.4.1.2 Statistical analysis of the ICD labelling in the point mutant and donors  
To determine which statistical test is suitable for the samples, Levene‟s test of equal 
variances was used, and revealed a p-value of 0.08, which is not significant (p<0.05). 
Therefore the variance in „intensity per unit length‟ values between the point mutant and its 
donors were not significantly different. With this assumption of equal variance, a Post hoc 
Tukey test was performed (see Chapter 2.6) to determine whether there were statistical 
differences; and between which groups this significance occurred. The results of this test are 
found in Table 3.7 below.   
 
 
 
 
 
 
  
Group Group Significance 
Point mutant  
Age-matched donor1 0.000 
Age-matched donor 2 0.000 
Age-matched 
donor 1 
   Point mutant 0.000 
Age-matched donor 2 0.198 
Age-matched 
donor 2 
   Point mutant 0.000 
   Age-matched donor 1 0.198 
Table 3.7 Results from a Post Hoc Tukey test. The average intensity 
per unit length of the point mutant was found to be significantly 
different from age-matched donor 1 and 2.  
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As seen in Table 3.7 above, the intensity per unit length of the point mutant was significantly 
different from both age-matched donors (p <0.001). Column graphs were plotted using final 
average intensity per unit length values. The raw statistical data from SPSS is listed in the 
Appendix.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.12 A column graph representing the average intensity per unit length 
for LV samples from the FDCM point mutant, and its age-matched donors. The 
mean of the point mutant was significantly different from both age-matched donors.  
Donor 2 
Donor 1 
Intensity per unit length (gray value /μm) 
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3.4.1.3 Obscurin antibody-labelling of the Truncating mutant tissue 
As expected, the confocal micrographs of immunofluorescence labelled samples of the 
truncating mutant also showed that the antibody localises to the ICDs of cardiomyocytes. 
(Figure 3.13, white arrows). The negative control image for this patient did not show any 
background or non-specific staining (see Appendix A). As seen previously with the point 
mutant, the length and width of the ICDs in the truncating mutant varied within and between 
micrographs. This was again attributed to the effect of the tissue sectioning process itself. 
The length and area values for the truncating mutant and its age-matched donors were also 
logged directly from Metamorph
®
. Table 3.8 lists the mean length and mean area of ICDs for 
each confocal image of the truncating mutant; as well as the corresponding fluorescence 
intensity. Table 3.9 shows the mean values of length, area, and intensity for each image of 
age-matched donor 1. Table 3.10 lists the mean values of length, area, and intensity for each 
image of age-matched donor 2.  
The final average length of ICDs (highlighted in yellow) between the truncating mutant and 
age-matched donor 1, was not significant different from one another (p=0.10). The final 
average length of ICDs between the truncating mutant and age-matched donor 2, was also not 
significantly different from one another (p=0.53). 
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Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 3844582 26 225
B 4385475 27 238
C 4055673 24 267
D 3885658 25 229
E 4283309 26 239
F 4326277 25 249
G 4242483 26 219
H 4371683 27 255
I 4481863 27 227
J 3952400 24 244
Average 26 239
Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 4625472 28 268
B 4079238 25 233
C 4551539 26 219
D 4217861 27 247
E 4364286 27 235
F 4518771 29 268
G 4103498 29 248
H 4226516 24 262
I 4230511 25 239
J 4483878 29 209
Average 27 243
Image Fluorescence intensity (gray scale units) Length (μm) Area (μm2)
A 4497820 25 264
B 4289467 24 225
C 4511842 26 272
D 4542918 28 263
E 4763797 29 313
F 4350465 27 235
G 4764188 27 285
H 4193353 25 232
I 4221646 25 211
J 4320846 25 202
Average 26 250
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
Table 3.8 Average length and area values for the truncating mutant The 
final calculated average values for length are highlighted in yellow at the bottom 
of the table. The final average value for area is highlighted in blue.  
 
Table 3.9 Average length and area values for age-matched donor 1  
 
Table 3.10 Average length and area values for age-matched donor 2 
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The final average area of ICDs for the truncating mutant and its age-matched donors is 
highlighted in blue in Tables 3.8-3.10. The average area of ICDs calculated for the truncating 
mutant was not found to be significantly different to age-matched donor1 (p=66). There was 
also no significant difference in the average area of ICDs, when compared to age-matched 
donor 2 (p=0.37). 
Table 3.11 below shows the intensity per unit length values obtained from the micrographs in 
Figure 3.13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.11 Intensity per unit length values for the truncating mutant. 
These measurements were obtained by dividing fluorescence intensity by 
length.  
 
Image Intensity per length
A 147869
B 162425
C 168986
D 155426
E 164743
F 173051
G 163172
H 161914
I 165995
J 164683
Average 162826
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Figure 3.13 (A-J) Confocal micrographs from a FDCM patient with a truncating 
mutation in the OBSCN gene (4.121) The FnIII obscurin antibody was labelled with a 
goat anti-rabbit Alexa Fluor® 488 secondary antibody. The obscurin antibody (labelled 
green) can be seen to localise to the intercalated discs of cardiomyocytes (white arrows). 
Images were taken at a 63x (NA 1.40) oil objective. Scale bar: 20μm. 
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Confocal images were also acquired from sections of two age-matched donors. The negative 
controls for these donors did not show any non-specific or background staining (see 
Appendix A).The fluorescence intensities of the ICDs were high in both donors (Figure 3.14 
& 3.15). The intense brightness of the ICDs is also evident in the truncating mutant, as seen 
in Figure 3.13. This observation is made clearer by the average intensity per unit length 
values for the truncating mutant (162,826 gray value units/μm) and its donors (161,854 gray 
value units/μm, 170,570 gray value units/μm). Final averages of intensity per unit length in 
Tables 3.11, 3.12, and 3.13, were used in the final statistical analysis (Chapter 3.4.1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.12 Intensity per unit length values calculated for age-matched donor 1. 
 
 
Table 3.13 Intensity per unit length values calculated for age-matched donor 2. 
 
 
Image Intensity per length
A 165195
B 163170
C 175059
D 156217
E 161640
F 155820
G 141500
H 176105
I 169220
J 154616
Average 161854
Image Intensity per length
A 179913
B 178728
C 173532
D 162247
E 164269
F 161128
G 176451
H 167734
I 168866
J 172834
Average 170570
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Figure 3.14 (A-J) Confocal micrographs of age-matched donor 1 (Patient 7.024). 
The FnIII obscurin antibody was labelled with a goat anti-rabbit Alexa Fluor® 488 
secondary antibody. The green labelling represents the obscurin antibody localising to 
the cardiac intercalated disc (white arrows). Images were taken at a 63x (NA 1.40) oil 
objective. Scale bar: 20μm. 
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Figure 3.15 (A-J) Confocal micrographs of age-matched donor 2 (Patient 6.038).  
Obscurin here is seen as the green labelling (white arrows), with the antibody 
targeting the fourth FnIII domain. The secondary antibody used was a goat anti-rabbit 
Alexa Fluor® 488. Images were taken at 63x (NA 1.40) magnification. Scale bar: 
20μm. 
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3.4.1.4 Statistical analysis of the truncating mutant using Intensity per unit length 
values 
Levene‟s test of equal variances between the truncating mutant and its donors revealed a p-
value of 0.36, which is not significant (p<0.05). Therefore the variance in intensity per unit 
length values was the same between the truncating mutant and its donors. Since it was found 
that there was equal variance across groups, it was suitable to use a Post hoc Tukey test. This 
determined whether there were statistical differences; and between which groups the 
significance occurred. The results of this test are found in Table 3.14 below.  
 
 
 
 
 
  
Group Group Significance 
Truncating mutant 
    Age-matched donor 1 0.962 
    Age-matched donor 2 0.108 
Age-matched 
donor 1 
    Truncating mutant 0.962 
    Age-matched donor 2 0.063 
Age-matched 
donor 2 
   Truncating mutant 0.108 
   Age-matched donor 1 0.063 
Table 3.14 Results of the Post hoc Tukey test.  
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The results of Table 3.14 show that there is no significant difference in the average intensity 
per unit length values; between the truncating mutant and donor 1 (p=0.96), and the 
truncating mutant and donor 2 (p=0.11). Since the point mutant did result in a significant 
difference in intensity per unit length, a similar result was expected for that of the truncating 
mutant (see Discussion Chapter 5.1). The raw statistical data from SPSS is listed in Appendix 
B.  
 
 
 
 
 
 
 
 
 
  
Figure 3.16 Column graph representing the intensity per unit length averages of 
the truncating mutant and its age-matched donors. There were no significant 
differences between the truncating mutant and its donors.   
Intensity per unit length (gray value /μm) 
Donor 2 
Donor 1 
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3.4.2 Comparative study: Measuring intensity per unit area of ICDs  
By measuring intensity per unit area, the width of ICDs was considered. Intensity per unit 
area would confirm if there was still a significant difference in the level of FnIII antibody; 
between the obscurin mutants and their donors. In this case, average intensity per unit area 
measurements of ICDs were calculated for both the point mutant and truncating mutant, as 
well as for their age-matched donors.   
3.4.2.1 The point mutant  
Tables 3.15, 3.16, & 3.17 show the intensity per unit area values for the point mutant, age-
matched donor 1, and age-matched donor 2; respectively. By observing the average intensity 
per unit area values in each case, it is clear that the average intensity per unit area of the point 
mutant is much lower compared to its age-matched donors. Final averages of intensity per 
unit area in Tables 3.15, 3.16, and 3.17 were used in the final statistical analysis (Chapter 
3.4.2.2). 
 
 
 
 
 
 
 
 
 
 
  
Table 3.15 Intensity per unit area values calculated for the 
point mutant. 
 Image Intensity per area
A 7267
B 6609
C 7998
D 7531
E 7509
F 7388
G 7629
H 6430
I 6993
J 6061
Average 7142
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Table 3.16 Intensity per unit area values calculated for age-
matched donor 1 
 
Table 3.17 Intensity per unit area values calculated for age-
matched donor 2 
 
Image Intensity per area
A 18595
B 20531
C 18688
D 19439
E 18598
F 17457
G 17448
H 18727
I 17202
J 18540
Average 18523
Image Intensity per area
A 18030
B 17112
C 17395
D 19441
E 18703
F 18589
G 19577
H 18905
I 19164
J 20869
Average 18778
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3.4.2.2 Statistical analysis of the point mutant using Intensity per unit area values 
Levene‟s test of equal variances revealed a p-value of 0.14, which is not significant (p<0.05). 
Therefore the variance in intensity per unit length values was the same between the point 
mutant and its donors. Since there was equal variance between the point mutant and donor 
values, a Post hoc Tukey test was performed to determine whether there were statistical 
differences. The results of this test are found in Table 3.18. The raw statistical data from 
SPSS is listed in Appendix B. 
 
 
 
 
 
 
 
 
 
 
As seen in Table 3.18, a significant difference (p<0.05) was found between the point mutant 
and both donors. This result shows that the average intensity per unit area of ICDs in the 
obscurin mutant is also significantly different from its donors. Figure 3.17 represents the 
mean difference as a column graph. The difference in average intensity per unit area is clearly 
evident in the graph.  
Group Group Significance 
Point mutant 
  Age-matched donor 1 0.00 
  Age-matched donor 2 0.00 
Age-matched 
donor 1 
  Truncating mutant 0.00 
  Age-matched donor 2 0.799 
Age-matched 
donor 2 
  Truncating mutant 0.00 
  Age-matched donor 1 0.799 
Table 3.18 Results from a Post hoc Tukey test. The mean difference of 
intensity per unit area between the point mutant and its donors was found 
to be significant.  
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Figure 3.17. Column graph representing the intensity per unit area averages of the 
point mutant and its age-matched donors. The significance in the means was found 
between the point mutant and its age-matched donors.  
Intensity per unit area (gray value 
units/μm) 
Donor 2 
Donor 1 
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3.4.2.3 Truncating mutant and its donors 
As seen in Tables 3.19, 3.20, &3.21 below, the intensity per unit area average of the 
truncating mutant is similar in magnitude to both of its age-matched donors. This is 
confirmed by the confocal images (Figure 3.13, 3.14 &3.15), whereby the brightness of the 
ICDs appears the same for all samples. Final averages of intensity per unit area in Tables 
3.19, 3.20, and 3.21 were used in the final statistical analysis (Chapter 3.4.2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.19 Intensity per unit area values calculated for the 
truncating mutant. 
 
Table 3.20 Intensity per unit area values calculated for age-
matched donor 1 
 
Image Intensity per area
A 17108
B 18459
C 15216
D 16953
E 17909
F 17398
G 19376
H 17138
I 19714
J 16199
Average 17547
Image Intensity per area
A 17275
B 17523
C 20802
D 17084
E 18591
F 16886
G 16569
H 16133
I 17675
J 21477
Average 18002
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3.4.2.4 Statistical analysis of the truncating mutant using Intensity per unit area values 
For this statistical comparison, a Post hoc Tukey test was also used. Equal variance between 
samples was found, since Levene‟s test revealed a p-value of 0.66. The results of the Post hoc 
Tukey test are listed below in Table 3.22. 
 
 
 
 
  
Group Group Significance 
Truncating mutant 
  Age-matched donor 1 0.817 
  Age-matched donor 2 0.821 
Age-matched 
donor 1 
  Truncating mutant 0.821 
  Age-matched donor 2 1.00 
Age-matched 
donor 2 
  Truncating mutant 0.821 
  Age-matched donor 1 1.00 
Table 3.22 Results from a Post hoc Tukey test. The average intensity 
per unit area of the truncating mutant was not found to be statistically 
significant from either of its age-matched donors. 
 
Table 3.21 Intensity per unit area values calculated for age-
matched donor 2 
 Image Intensity per area
A 17063
B 19082
C 16615
D 17281
E 15208
F 18517
G 16727
H 18061
I 19987
J 21424
Average 17996
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As seen in Table 3.22, there was no significant difference in average intensity per unit area 
between the truncating mutant and its age-matched donors (p>0.05). Figure 3.18 presents this 
data as a column graph, showing the final averages of intensity per unit area for the 
truncating mutant and its donors. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
Figure 3.18 Column graph representing the intensity per unit area averages of 
the truncating mutant and its age-matched donors. There was no significant 
difference in intensity per unit area found with relation to the truncating mutant and 
its donors.  
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4.1 Introduction 
The available published literature on the giant protein obscurin have relied solely on animal 
models (mainly mice) to determine the location of its isoforms in the cardiac sarcomere 
(Borisov et al., 2004; Borisov et al., 2008; Kontrogianni-Konstantopoulos et al., 2004; 
Kontrogianni-Konstantopoulos et al., 2006; Young et al., 2001; Bang et al., 2001).  
This chapter builds on the above published literature and attempts to describe the precise 
locations of obscurin A and obscurin B isoforms in left ventricle (LV) sarcomeres from non-
failing, healthy human donors. In particular it will attempt to resolve a controversy over the 
location of this giant protein in the sarcomere.  Is obscurin located at the M-line, the Z-disc, 
or both? Using immunohistochemistry, this study will use two anti-obscurin antibodies that 
were characterised in detail and kindly donated by Dr Kontrogianni-Konstantopoulos and her 
colleagues using the mouse heart in their laboratory at the University of Maryland.  
One, called the “Ig1/2 obscurin” antibody, is directed against epitopes in the first two 
immunoglobulin domains that are common to the giant isoforms of obscurin. The second 
antibody targets the fourth fibronectin domain only found in obscurin B and the short kinase 
isoforms; and is located towards (but not at) its C-terminus.   
The principal objective of the chapter is to identify the locations of the two ends of this 
important protein in the human cardiac sarcomere, thereby providing a structural framework 
for interpreting how it might function.  
This Chapter will focus on: (1) Confirming that the observations described above for the 
mouse are also true for healthy human donor left ventricles; (2) Identifying the locations of 
the two “ends” of obscurin in the half-sarcomere; and (3) identifying non-sarcomere 
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locations, particularly in relation to the cardiomyocyte nuclear membranes, the cardiac 
sarcolemma and the intracellular sarcoplasmic reticulum. 
Note: All confocal images in this Chapter were taken using a Zeiss LSM 510 Meta Confocal 
microscope. 
 
4.2 Immunolocalisation of obscurin using the Ig1/2 obscurin antibody 
The localisation of obscurin using the Ig1/2 obscurin antibody was investigated using donor 
tissue from the LV of a 23 year-old (yo) (Patient No. 4.013). Figure 4.1A &B shows typical 
staining using the Ig1/2 obscurin antibody and a goat anti-mouse Alexa Fluor® 568 dye. The 
staining of this antibody gives the tissue a striated appearance. This suggests that the obscurin 
antibody targeting the Ig1/2 domains of obscurin, should localise to either the M-line or the 
Z-disc.  
To determine exactly where this antibody localises, it was co-stained with alpha actinin (α-
actinin). This protein is known to localise to the peripihery of the Z-disc, and therefore was 
used as a sarcomeric marker in the study. Figure 4.2B shows the results of immunostaining, 
using the α-actinin antibody that targets isoform 1 and 4 of α-actinin. It was labelled with a 
goat anti-rabbit Alexa Fluor® 488 dye. Here, the Z-disc is represented by thin black slits 
(white arrows) between pairs of distinct green bands. The green bands represent isoforms 1 
and 4 of α-actinin (which commonly stain in this manner).  
Figure 4.2C shows a single dual-channel confocal Z-slice (0.30µm) of tissue labelled with 
both the obscurin (red) and α-actinin (green) antibodies. By using α-actinin as a marker for 
the Z-disc, it could be determined that the obscurin antibody (targeting Ig1/2), localises to the 
M-line in human LV donor tissue.  
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Figure 4.1 Immunofluorescence labelling of the Ig1/2 obscurin antibody in human LV 
donor tissue (A) Staining of the Ig1/2 obscurin antibody labelled with a secondary goat anti-
mouse Alexa Fluor® 568 antibody. (B) Confocal micrograph representing staining of the Ig1/2 
obscurin antibody. Nuclei were stained with DAPI (blue). In both micrographs, the striated 
appearance suggests that the Ig1/2 obscurin antibody localises to either the M-line or the Z-disc.  
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Figure 4.2 Confocal micrographs of obscurin and α-actinin labelling in human LV 
tissue. (A) Staining pattern using the obscurin antibody targeting the Ig1/2 domains, 
labelled with a secondary goat anti-mouse Alexa Fluor® 568 antibody. (B) Confocal 
micrograph representing staining of the α-actinin antibody. It was labelled with an Alexa 
Fluor® 488 dye. The staining of α-actinin is seen as distinct pairs of green bands running 
parallel to each other. The thin black line in the middle of each pair represents the Z-disc 
(white arrows). (C) Overlay image showing alpha-actinin at either side of each Z-disc, and 
the obscurin antibody at the M-line (Z-slice thickness, 0.30 µm). All images were taken at 
100x (NA 1.40) oil objective. Scale bar: 5μm.  
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4.3 Immunolocalisation of the FnIII obscurin antibody 
As mentioned previously, the FnIII obscurin antibody targets the fourth FnIII domain. This 
domain is found on obscurin B and its smaller isoforms (Chapter 1, Figure 1.9); and also on 
the smaller kinase isoforms. When the C-terminal obscurin antibody was stained on donor 
LV tissue, it appeared as pairs of striations running parallel to one another (Figure 4.3, white 
arrows).  
The dark space (Figure 4.3, red arrows) between each pair was considered to be either the M-
line or the Z-disc. The ICDs in Figure 4.3 are oversaturated, as the concentration of the 
antibody had to be increased in order to make the sarcomere staining more apparent. There 
was no oversaturation of the sarcomeric staining. Figure 4.3A shows labelling of a LV 
section from a 48 yo donor (4.095), and Figure 4.3B shows labelling of a LV section from 
that of a 40 yo donor (3.069). 
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Figure 4.3 Immunostaining of the FnIII obscurin antibody in LV donor tissue                     
(A) Obscurin (FnIII) labelling (green), using a secondary Alexa Fluor® 488 dye. In this first 
donor tissue, obscurin labelling occurs as pairs of parallel bands (white arrows). Between each 
pair is a black gap (red arrows), which is predicted to be either the M-line or the Z-disc. (B) FnIII 
obscurin antibody staining of LV tissue from a second donor. Both images were taken at 100x 
(NA 1.40) oil objective. Scale bar: 10μm. 
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To further determine the location of the FnIII obscurin labelling, an antibody to α-actinin 2 
was used as a sarcomeric marker of the Z-disc. This particular study used LV tissue from a 23 
yo male donor (4.013), which was also used for the study of the Ig1/2 obscurin antibody 
(Chapter 4.2). The staining of α-actinin is shown in the confocal image of Figure 4.4A.  
Figure 4.4B shows the 488nm channel of a confocal image of the FnIII obscurin antibody 
using a goat anti-rabbit Alexa Fluor® 488 dye. The antibody localises in pairs of bands, 
although the paired effect is not as obvious as it was in Figures 4.3 A and B.  The large voids 
between myofibrils in Figure 4.4 possibly represent ice crystal damage formed either during 
the tissue preparation or during the warming of the tissue block from -196°C or the 
cryosection from -25°C.  
Closer inspection of the 488 nm channel reveals much fainter bands of obscurin between the 
stained Z-disks. This was not so evident in the images shown in Chapter 3 and this pattern is 
discussed below in more detail in Figure 4.5. 
There is an interesting feature of the ICDs imaged in Figure 4.4B. Closer inspection of these 
discs reveals they are stained heavily on either side with a distinct gap or reduced staining in 
the middle. And finally there is clear staining of a structure that lies parallel to but between 
the myofibrils which is described below with Figure 4.5. 
In Figure 4.4B the ICDs are strongly-stained by the FnIII antibody (as seen Chapter 3.1). Co-
staining of both obscurin (488 nm channel) and α-actinin (568 nm channel) is shown in 
Figure 4.4C. Alpha actinin (red) is clearly seen running through the previously-observed 
black gaps (Figure 4.3, red arrows). This means that the obscurin FnIII antibody (green) 
localises as a constant band on both sides of the Z-disc.  
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To observe the co-staining in closer detail, a region of Figure 4.4C was magnified (white 
inset). This inset is shown in Figure 4.5. This Figure clearly shows α-actinin (blue arrows) 
running between the parallel striations of obscurin (white arrowheads). Since Figure 4.5 is 
enlarged, image C reveals that the FnIII obscurin antibody also stains the M-line faintly. 
There is also evidence of staining at the sarcoplasmic reticulum, seen here as the longitudinal 
green lines, running parallel to the direction of the cardiomyocytes.  
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Figure 4.4 Donor heart tissue co-stained with FnIII obscurin and α-actinin 
antibodies (A) Staining of α-actinin, showing labelling at the Z-disc (B) FnIII 
obscurin antibody labelling using an Alexa Fluor® 488 secondary antibody. Staining 
of the ICD is also evident in this image. (C) Overlay image showing staining of FnIII 
obscurin and α-actinin. Here, obscurin localises to either side of each Z-disc, but does 
not colocalise with the region. The white inset represents a cropped region. Z-slice 
image (0.10 µm). These images were taken at 100x (NA 1.40) oil objective. Scale bar: 
10μm.  
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Figure 4.5 Inset from Figure 4.4C (A) Immunofluorescence labelling using the anti-α-
actinin 2 antibody and an Alexa Fluor® 568 secondary antibody. Note here that α-actinin 
(red) stains the Z-disc. (B) Anti-obscurin antibody labelled with an Alexa Fluor® 488 
secondary antibody (C) Overlay showing staining of the FnIII obscurin antibody (white 
arrowheads) and α-actinin (blue arrows). In each case, the obscurin antibody (green) is 
juxtaposed to either side of the Z-disc (red), and faint staining is evident at the M-line (the 
M-line bisects adjacent Z-discs). Staining is also present at the sarcoplasmic reticulum 
(longitudinal green lines running along the length of the CM), and at the ICD. Scale bar: 
2μm.  
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Further imaging was performed on additional donor tissues to confirm these findings. The 
confocal images in Figure 4.6 are from a LV section of a 31 yo donor (5.140). Figure 4.7 
represents micrographs from the LV of a 55 yo donor (4.062), and Figure 4.8 shows obscurin 
staining from the LV of a 29 yo donor (5.086). In all three figures, the localisation of the 
FnIII obscurin antibody on adjacent sides of the Z-disc is clearly evident. In addition, 
staining of the sarcoplasmic reticulum is also seen, running through the middle of  
cardiomyocytes, and parallel to them (Figure 4.7C & 4.8C). Furthermore, staining at the 
sarcolemma is also seen in Figure 4.7C and 4.8C. They appear as longitudinal lines running 
between the borders of the myofibrils.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
A 
Figure 4.6 Confocal images showing staining of FnIII obscurin and α-actinin antibodies 
(A) Anti- α-actinin antibody labelled with an Alexa Fluor® 568 secondary antibody, staining 
the Z-disc (red) (B) Anti-obscurin antibody labelling using an Alexa Fluor®  488 secondary 
antibody (C) Overlay image showing co-staining of FnIII obscurin and α-actinin (D) Magnified 
image of C. Obscurin (purple arrowheads) localised to each side of the Z-discs (white arrows). 
Z-slice image (0.30 µm). All images taken at 00x (NA 1.40) oil objective. Scale bar: 5μm. 
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Figure 4.7 Confocal images from donor tissue stained with antibodies against FnIII 
obscurin and α-actinin. (A) Staining of α-actinin, representing the Z-disc (red) (B) 
Immunostain of the C-terminal obscurin antibody labelled with an Alexa Fluor® 488 
secondary antibody (C) Confocal micrograph showing co-staining of FnIII obscurin and α-
actinin. Here, obscurin (purple arrows) is clearly seen to localise to adjacent sides of each 
Z-disc (white arrows). Z-slice image (0.20 µm). Images were taken at 100x (NA 1.40) oil 
objective. Scale bar: 2μm. 
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Figure 4.8 Confocal images showing staining of the FnIII obscurin and α-actinin 
antibodies (A) Immunostain of α-actinin (red) (B) Immunostain of the FnIII obscurin 
antibody (C) Confocal micrograph showing co-staining of FnIII obscurin and α-
actinin. Obscurin (purple arrows) localises to adjacent sides of each Z-disc (white 
arrows). Z-slice image (0.50 μm). All images taken at 100x (NA 1.40) oil objective. 
Scale bar: 10μm.   
A 
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 Figure 4.9 Co-staining of the Ig1/2 and FnIII obscurin antibodies in 
LV donor tissue (A) Confocal micrograph showing co-staining of both 
the Ig1/2 (red), and the FnIII obscurin antibody (green)  (B) A magnified 
image from A. The paired band- like staining of the FnIII obscurin 
antibody (blue arrows) is again apparent. Staining of α-actinin is indicated 
by the yellow arrowheads. Images obtained using a Zeiss LSM 510 Meta 
Confocal microscope at 100x (NA 1.40) oil objective. Scale bar: 10μm. 
4.4 Double staining of obscurin antibodies 
The Ig1/2 antibody and the FnIII antibody to obscurin were used to co-stain a LV section 
from a 42 yo donor (6.056). As seen in Figure 4.9, the Ig1/2 antibody (red) localises to the M-
line, while the Fn (III) antibody (green) localises to adjacent sides of the Z-disc. However this 
does not mean that obscurin spans the length of the half-sarcomere, since the FnIII antibody 
targets smaller kinase isoforms, while the Ig1/2 antibody targets the two main large isoforms: 
Obscurin A & B. 
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When the fluorescence in Figure 4.9A was observed using only the red (568 nm) channel, the 
Ig1/2 obscurin antibody faintly stained the ICD. Staining of the Ig1/2 obscurin antibody in 
the ICDs of Figure 4.9A was isolated using Metamorph
®
 and fluorescence intensity was 
measured.  
The presence of the N-terminal Ig1/2 obscurin antibody at the ICD is shown in Figure 4.10. It 
therefore probably belongs to either obscurin A or B, since these are the two major isoforms 
expressed in cardiac muscle. However, given the localisation of the FnIII antibody at the ICD 
(Figure 4.9), it is more probable the red lines in Figures 4.10-11 belong to the N-terminal 
region of obscurin B. 
The fluorescence intensity of each of these ICDs was quantified using Metamorph (see 
Chapter 2 Methods) and the data are summarised in the table of Figure 4.10.  The intensities 
are consistent with assumption that this N-terminal Ig1/2 obscurin antibody probably is 
present in the ICDs. The staining of the antibody is more evident at the borders of the ICDs 
(Figure 4.10).  
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ICD object number Fluorescence intensity (gray value units) 
1 589717 
2 255578 
3 113466 
4 85977 
5 175166 
6 391692 
1 
2 
3 
4 
5 
6 
Figure 4.10 Localisation of the Ig1/2 obscurin antibody to the ICD (A) 
Localisation of the Ig1/2 obscurin antibody to the ICD. (Table) Fluorescence 
intensity values corresponding to each numberd ICD in the micrograph above.  
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Further analysis was done in another region of the donor tissue to confirm the finding. Figure 
4.11 below represents localisation of the Ig1/2 obscurin antibody to ICDs. The corresponding 
fluorescence intensities are also listed in the table. In ICD number 3, the staining of the 
obscurin antibody is again seen to localise at the borders of the intercalated disc.  
 
 
 
 
 
 
 
  
ICD object number Fluorescence intensity (gray value units) 
1 174081 
2 180015 
3 429689 
4 188320 
5 66412 
1 
2 
3 
4 
5 
Figure 4.11 Localisation of the Ig1/2 obscurin antibody to the ICD (A) 
Localisation of the Ig1/2 obscurin antibody to the ICD. (Table) Fluorescence 
intensity values corresponding to each numberd ICD in the micrograph above.  
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4.5 Perinuclear staining 
The FnIII obscurin antibody also strongly localises to the perinuclear region of cell nuclei 
(indicated by red arrows).  This staining has a granular or punctate appearance and seems to 
correspond to the nuclear membranes of the cardiomyocytes (based on the central location of 
the DAPI-stained cardiomyocyte nuclei).  
Not all nuclear membranes in these images stain with this C-terminal antibody. For example, 
the nuclei (blue arrows) seen at the edges of capillaries appear to be endothelial cell nuclei, 
and the nuclei seen between the cardiomyocytes (green arrows) probably belong to 
leukocytes that have infiltrated the LV.  
The thick green bands label the ICDs and the finer green lines running parallel to the 
cardiomyocytes highlight their sarcolemma membranes. As discussed above, this staining 
probably belongs to obscurin B (rather than the small kinase isoforms that also carry the FnIII 
domains) because it also stains the sarcomere with a wide stain at the Z disc and a finer line 
at the M-line. The micrographs in Figure 4.12 show this localisation in the LV of various 
donor tissues.    
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Figure 4.12 Perinuclear staining of obscurin in various donor tissues. The red arrows 
indicate the location of obscurin in relation to the nucleus. It is clear that obscurin 
surrounds the nucleus in a border-like fashion, and hence is most likely residing in the 
perinuclear region (A) & (B) Confocal micrographs imaged from the LV section of a 19 
yo donor (7.012) (C) & (D) Confocal micrographs imaged from the LV section of a 33 
yo donor (7.054). All images were taken at 63x (NA 1.40) oil objective. Scale bar: 20μm.  
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4.6 Conclusions 
On the basis of the images and data presented in this Chapter, the following conclusions may 
be drawn: 
(1) Human left ventricle cardiomyocytes express obscurin A and B as well as the small 
kinase isoforms of obscurin.  
(2) In the sarcomere: (i) The N-terminal Ig1 and Ig2 domains of obscurin (present in most 
isoforms including obscurin A and B) are located exclusively at the sarcomere M-
lines and is not observed at the Z discs; (ii) The FnIII domain (located towards the C-
terminus of obscurin B) is located in the I band, close to but not co-localised (i.e. 
coincident) with the Z disc. 
(3) Obscurin B was identified by the presence of the Ig1/2 domains (present in obscurins 
A and B) combined with the FnIII domain, which is absent in obscurin A. 
(4) A relatively small fraction of the total obscurin N-termini and a similarly small 
expression of the FnIII domain is located in the ICD. 
(5) Cardiomyocyte nuclear membranes stain with the C-terminal FnIII antibody, which 
does not stain non-cardiomyocyte nuclear membranes. 
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5.1 Comparing the expression of obscurin isoforms in failing and non-failing hearts 
Next generation sequencing (NGS) of 30 FDCM patients initially revealed that five patients 
carry a mutation in OBSCN. There were no remaining LV samples of three of these patients 
(1.041, 1.059, and 3.070), leaving the study with two remaining FDCM patients. NGS of 
FDCM patient 4.121 initially indicated there was a truncating mutation, while the second 
FDCM patient (2.066) contained a single point mutation. 
Chapter 3 provided the first comparison of obscurin expression at the intercalated discs in 
these FDCM patients and age-matched healthy donor hearts, using quantitative confocal 
microscopy. The preliminary data show that obscurin expression is down-regulated in the 
ICDs from the patient carrying a single amino acid substitution (E963K) in the Ig-like 
domain 9 (Table 3.7 and Figure 3.12).  
When data from the FDCM patient with end-stage HF but no obscurin mutation were 
compared to the donors, there was a small but not statistically significant difference. This 
suggests that the obscurin levels of patients with end-stage HF do not change. This is 
consistent with the recent report by Marston et al. (2015). 
Returning to the point mutation (E963K), this specific domain has no known functions but it 
is close to the sequence that binds both myomesin and the C-terminus of titin. The data 
presented in this thesis suggest that the small kinase isoforms of obscurin and obscurin B are 
the likely candidate proteins that are down-regulated. More research will be needed to 
establish this mutation as causative of the FDCM phenotype. The modest but significant loss 
of this protein suggests it may result in a haplotype insufficiency. Certainly, the substitution 
of glutamate for a lysine would result in a change from a negative to a positive charge in the 
Ig-like 9 domain.  Residue C962 is a cysteine which may become oxidised to form a cystine 
bond. Residue S961 is a serine, which is a common site for phosphorylation. However, 
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establishing whether oxidation or phosphorylation actually occurs will require careful mass 
spectrometry and this is beyond the scope of this thesis.  
The recent report (Marston et al., 2015) concluded that this residue was not the site of a 
single nucleotide polymorphism (SNP) seen in healthy individuals. Probably the most 
interesting evidence regarding causality is the fact that NGS and pyrosequencing uncovered 
no other mutations in this patient. 
Fluorescence microscopy employed in Chapter 3 contains a quantitative analysis of the 
protein levels of the C-terminal FnIII domain of obscurin B. This microscopy enables the 
study to focus on changes in the expression levels of obscurins in intercalated discs 
containing this epitope. The analysis examined obscurin expression levels (intensity) relative 
to both the length and (considering their substantial thickness), the area of ICDs. Intensities 
of both showed there was significantly less FnIII expressed (intensity per unit length or 
intensity per unit area) in the ICDs in the patient with the point mutation. This reduction may 
well belong to obscurin B identified on the basis of the N-terminal antibody (see Chapter 4). 
Western blot analysis of obscurin expression can only detect average overall changes to 
protein expression in bands that were positive for both the N-terminus and the FnIII domain. 
Since the majority of obscurin B is sarcomeric, its downregulation would be difficult to 
detect. Furthermore, changes in the small kinase isoforms would only be detected if they 
were predominantly expressed in the ICD. However, these isoforms are also expressed in the 
sarcolemma, sarcoplasmic reticulum and in the perinuclear zone of the cardiomyocytes (see 
Chapter 1). This, coupled with the fact that the two available obscurin antibodies target 
domains shared by most isoforms, would not be sufficient to specifically determine which 
isoforms of obscurin were being down regulated and in which areas of the cell this 
downregulation occurred.  
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The obscurin antibody used in Chapter 3.4 targeted isoforms of obscurin bearing the fourth 
FnIII domain. Since the smaller cardiac-specific kinase isoforms of obscurin contain the 
fourth FnIII domain, it was concluded that the fluorescence intensity, and hence protein 
expression of these isoforms was significantly downregulated in the point mutant.  
Interestingly, the many obscurin splice isoforms bearing the fourth FnIII domain (Chapter 1, 
Figure 1.9) also contain the SK1 domain. This is particularly true with the smaller cardiac-
specific isoforms of obscurin that directly interact with the 1 subunit of the Na+/K+ ATPase 
pump (NKAβ1) (Hu and Kontrogianni-Konstantopoulos, 2013). This binding occurs at the 
sarcolemma, the ICD, and the t-tubules. Biochemical studies show that small obscurin-kinase 
isoforms (~55-70 kDa) take part in this interaction (Hu and Kontrogianni-Konstantopoulos, 
2013).  Although the importance of SK1/NKAβ1 interaction is still unclear, it is possible that 
the lower expression of the smaller kinase isoforms disrupts the SK1/NKAβ1 binding and 
therefore contributes to the development of HF.   
Down regulation of obscurin B containing the fourth FnIII domain could also affect titin 
distribution in humans. Down-regulation of obscurin in rat cardiomyocytes alters titin 
distribution and alignment within the sarcomere (Borisov et al., 2006). If obscurin 
downregulation affects this interaction in animal models, then it is likely that mutations in 
obscurin may also affect the normal functioning of titin in humans. Truncating mutations in 
titin are a major cause of FDCM (Herman et al., 2012), and in light of the above, it is 
possible that this disruption may play causative roles in patients suffering an obscurin 
mutation in its titin-binding regions (see Chapter 1, Figure 1.9). 
There was no significant difference in the intensity per unit length values, between the 
truncating mutant and its two age-matched donors. Furthermore, no significance between 
groups was found when using intensity per unit area measurements. This finding was at first 
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surprising, considering the location of the truncation. The putative truncating mutation occurs 
at residue 998, with a frameshift that extends for 85 amino acids, before encountering a stop 
codon.  
Considering the size of large obscurin isoforms (6200-8000 amino acids), this mutation is 
near the N-terminus. Such a mutation is unlikely to be expressed. If upregulation of the wild-
type allele was unable to compensate, this haplotype insufficiency could result in HF. This is 
in fact the case for myosin binding protein C in familial hypertrophic cardiomyopathy 
(Carrier et al., 1997). 
Only recently, pyrosequencing was performed on these FDCM patients used in this thesis. It 
was discovered that the NGS mutation for the truncating mutation was in fact a sequencing 
error. Thus, the lack of a significant difference in expression level is consistent with this new 
sequencing data. It also validates our method of using fluorescence intensity to quantify the 
level of obscurin expression between mutants and controls.  
5.2 Localisation of obscurin at the ICD 
The finding in Chapter 3 that both obscurin and connexin-43 are expressed in the ICD has 
never been reported for human heart (Figures 3.1 and 3.2), but was known in mice (Hu and 
Kontrogianni-Konstantopoulos, 2013).  Further analyses were performed using Bitplane 
Imaris software on several donor tissues.  
The use of Pearson‟s correlation coefficient to measure the degree of colocalisation was 
beneficial, since it is not sensitive to background noise (Dunn et al., 2011), and is not affected 
by signal shift (Adler and Parmryd, 2010).  In theory, Pearson‟s values close to 1 indicate a 
high degree of correlation between two pixels, in this case green (obscurin) and red 
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(connexin-43) pixels. However the values (0.77-0.85) found at the ICD (Section 3.2) were 
low.  
The values above indicate a low but existing correlation between obscurin and connexin-43 at 
the ICD, but the micrographs in Chapter 3 confirm that they are not precisely coincident. The 
3D projection from a Z-stack provides a better insight into the arrangement of these proteins 
(Figure 3.6D). Here, the pixels from each channel merely conincide within the same space 
(ICD), but do not directly colocalise to form the yellow colour most associated with direct 
colocalisation. 
The presence of obscurin isoforms at the ICD correlates with its many functions. For 
example, the obscurin SK2 domain (Figures 1.9A, 1.9B, and 1.9D) directly binds to and 
phosphorylates the cytoplasmic domain of N-cadherin, a major player of cell-cell adhesion 
(Mezzano and Sheikh, 2012). The interaction also occurs at the level of the ICD (Hu and 
Kontrogianni-Konstantopoulos, 2013). Thus, it is possible that SK2 contributes to the 
mechanochemical coupling of cardiomyocytes at the ICD via phosphorylation, and that it 
regulates the activities of N-cadherin.  
Imaging ICDs with the new Zeiss LSM 810 confocal microscope revealed a stack-like pattern 
of FnIII staining, and led to the prediction that obscurin localises to the adherens junction of 
the ICD. This prediction was based on adherens junction in electron micrographs, shown in 
Figure 5.1 (Severs 1994; Bennett et al., 2006).  
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The arrows in Figure 5.1 point to the locations of the adherens junction, found on the folds of 
the plicate region, and proposed to be labelled by the FnIII obscurin antibody. They 
correspond to the stack-like staining pattern of obscurin in Figure 3.8A.  
 
  
Figure 5.1 Electron micrographs of the adherens junction in a cardiac 
intercalated disc. The white arrows point to regions of the adherens junction that 
are proposed to be labelled by the FnIII obscurin antibody in Figure 3.8A. The 
hollow arrowhead in (B) points to the position where last myofibrils attach to the 
ICD. [Image A obtained from Severs 1994, and Image B obtained from 
Bennett et al., 2006].  
A 
B 
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5.3 Localisation of obscurin in the human cardiac sarcomere 
Chapter 4 describes for the first time the locations of obscurin in the human cardiac 
sarcomere. Overall, the findings confirmed previous observations in rats and mice (see 
Chapter 1) that it is found at the M-line. 
This is the most commonly observed location of obscurin in animal models of cardiac 
sarcomeres. In the M-line, obscurin plays a significant role in the normal functioning of the 
sarcomere. At the periphery of the cardiac M-line, the C-terminus of titin, the Ig1-Ig3 
domains of obscurin, and the myosin cross-linking protein myomesin, form a multimolecular 
complex that is crucial for the function of the M-line as a mechanical link (Fukuzawa et al., 
2008; Pernigo et al., 2010). Ackermann et al. demonstrated that down-regulation of obscurin 
or overexpression of its second Ig domain, Ig2, which is the binding site for MyBP-C slow 
isoforms, inhibits the integration of the latter in forming the M-line (Ackermann et al. 2009).  
Taken together with the results of Chapter 3.1, it is likely that the down regulation of FnIII 
containing obscurin isoforms may have prevented its interaction with titin and myomesin at 
the M-line. If so, the contribution of this interacting complex to the stability of the M-line 
would have likely been reduced. Such an outcome would be one of many factors that 
eventually led to the development of cardiomyopathy in the FDCM patients with a point 
mutation. Interestingly, Pernigo et al. (2010) suggested that the stability of the M-line is 
achieved via a cooperative protein network, and disruption of that network, i.e. gene 
mutations, may contribute to the development of myopathies. 
The finding of obscurin at the M-line may also be important, with regards to its interaction 
with ankyrin-B. The obscurin-ankyrin-B interaction recruits protein phosphatase 2A (PP2A) 
to the M-line, in both neonatal and mature cardiomyocytes (Cunha and Mohler, 2008). PP2A 
is a Ser/Thr phosphatase that is known to regulate cardiac L-type calcium channels (Kamp 
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and Hell, 2000; Xu et al., 2010). For example, PP2A sensitises the myofilaments to Ca
2+
 as a 
result of troponin I dephosphorylation (Wijnker et al., 2011).  
Although the functional importance of recruiting PP2A to the M-line has not been fully 
resolved, it has been suggested that the obscurin/ankyrin B recruitment of PP2A regulates 
titin kinase (TK) activity (Mayans et al., 1998; Lange et al., 2005; Peng et al., 2007; Cunha 
and Mohler, 2008). The implications of this are not trivial because TK deficiency is 
embryonically lethal, as it impairs sarcomere maturation (Musa et al., 2006; Weinert et al., 
2006). PP2A activity is also increased in heart failure, and over-expression of its catalytic 
subunit results in dilated cardiomyopathy (Brewis et al., 2000).  
Hence it may be that obscurin regulates the localisation of ankyrin-B in the M-line, and 
together they could potentially modulate the activity of PP2A during pathological changes in 
DCM. Interestingly, others researches have reported that normal expression of ankyrin B 
protects the heart, and that loss of ankyrin B in humans is directly associated with cardiac 
damage and loss of function such as sinus node disease, atrial fibrillation, ventricular 
tachycardia, and sudden cardiac death- all consistent with the protective role of ankyrin B in 
the human heart (Kashef et al., 2012). This in turn suggests that the interactions of obscurin 
with ankyrin B are vital for the normal function of titin, PP2A, and ankyrin-B.  
While there is little or no controversy over the location of obscurin at the M-line, the same 
cannot be said about the Z disc. The FnIII antibody is present in obscurin B isoforms (Figure 
1.9) and is localised to adjacent sides of the Z-disc, (for example in Figures 4.3 A and B). 
Obscurin, initially present at the Z-disc later translocates to the M-line as cardiomyocytes 
mature (Young et al., 2001). Controversially, Chapter 4 reports it in the I-band adjacent to the 
Z-disc in adult donors. This may be due to its binding to a small isoform of titin, novex-3 
(Bang et al., 2001). This interaction involves the C-terminal end of novex-3 with the 
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Ig48/Ig49 domains of obscurin A and B at the I-band (Bang et al., 2001), see Figure 1.11. 
Since obscurin A and B contain the typical SH3 and Rho-GEF signalling domains, it is 
possible that the complex, via cell signalling, facilitates the mechano-sensing functions of 
titin during structural changes to the sarcomere. Granzier and Labeit (2002) further suggest 
that this signalling function may be of some importance in disease states.  
5.4 Limitations and Future studies 
Thse use of immunofluorescence to study the expression and localisation of obscurin has 
shown to be a useful approach to study obscurin, given its variability in both location and 
function within the myocardium. However, investigating the changes in the protein 
expression levels of obscurin in FDCM patients carrying a OBSCN mutation requires 
validation through the use of at least one other experimental approach; for example, Western 
Blot analysis. 
The finding that obscurin isoforms carrying the FnIIIdomain reside in the adherens junction, 
needs to be confirmed by further microscopy. With the use of a beta-catenin (β-catenin) 
antibody, colocalisation studies can be carried out with obscurin in the future. Any 
colocalisation between the two antibodies would allow researches to conclude that obscurin 
resides specifically to the adherens junction of the cardiac ICD.  
A further study might involve fluorescence resonance energy transfer (FRET) analysis 
between β-catenin and obscurin to determine whether they interact at the adherens junction. 
Binding studies could then be carried out to study the expression and localisation of obscurin 
and β-catenin in relation to one another. It could be that obscurin regulates the localisation of 
β-catenin to the adherens junction, or vice versa, and that their interaction is vital to the 
proper functioning of β-catenin as a signalling molecule. If so, it would be a significant 
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finding, as changes in the localisation and expression of β-catenin have been linked to DCM 
(Garcia-Gras et al., 2006; Schäfer et al., 2003).  
An important limitation to the findings of this thesis was the low sample number of FDCM 
patients carrying a mutation in the obscurin gene. Initially, five of 30 FDCM patients 
contained point mutations. Of those, only 2 were available for investigation. Of course, a 
future step could repeat the study of Chapter 3 using RV. Most importantly, more patients 
need to be screened via pyrosequencing. This is achievable, given the high number of IDCM 
patients present in the Sydney Heart Bank. With screening of such a large cohort of IDCM 
patients, it is certain that more patients will be revealed to contain a mutation in the OBSCN 
gene.  
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Negative control stain for the point mutant (20x) 
Negative control stain for the point mutants age-matched control 1 (20x) 
(20x) 
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Negative control stain for the point mutants age-matched control 2 (20x) 
Negative control stain for the truncating mutant (20x) 
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Negative control stain for the truncating mutants age-matched control 1 (20x) 
Negative control stain for the truncating mutants age-matched control 2 (20x) 
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Appendix B 
 
 Raw statistical data: Intensity per unit LENGTH measurements for the point mutant 
                                                                   Descriptive statistics 
 
 
 
 
 
 
 
 
 
 
 
 Post Hoc Tests 
Tukey HSD 
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 
Point Mutant 
Age-matched control 1 -113002.300
*
 5396.358 .000 
Age-matched control 2 -103435.400
*
 5396.358 .000 
Age-matched control 1 
Point Mutant 113002.300
*
 5396.358 .000 
Age-matched control 2 9566.900 5396.358 .198 
Age-matched control 2 
Point Mutant 103435.400
*
 5396.358 .000 
Age-matched control 1 -9566.900 5396.358 .198 
 
 N Mean Std. Deviation Std. Error 
Point Mutant 10 63830.20 9008.321 2848.681 
Age-matched control 1 10 176832.50 10079.443 3187.400 
Age-matched control 2 10 167265.60 15939.421 5040.487 
Total 30 135976.10 53325.410 9735.843 
Test of Homogeneity of Variances 
Intensity_per_length 
Levene Statistic df1 df2 Sig. 
2.815 2 27 .078 
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 Raw statistical data: Intensity per unit LENGTH measurements for the truncating 
mutant 
Descriptive statistics 
 
 
 
 
 
 
 
  
Test of Homogeneity of Variances 
Intensity_per_length 
Levene Statistic df1 df2 Sig. 
1.078 2 27 .355 
 
Post Hoc Tests 
Tukey HSD 
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 
Truncating mutant 
Age-matched control 1 972.200 3681.957 .962 
Age-matched control 2 -7743.800 3681.957 .108 
Age-matched control 1 
Truncating mutant -972.200 3681.957 .962 
Age-matched control 2 -8716.000 3681.957 .063 
Age-matched control 2 
Truncating mutant 7743.800 3681.957 .108 
Age-matched control 1 8716.000 3681.957 .063 
 N Mean Std. Deviation Std. Error 
Truncating mutant 10 162826.40 6986.067 2209.188 
Age-matched control 1 10 161854.20 10432.427 3299.023 
Age-matched control 2 10 170570.20 6761.022 2138.023 
Total 30 165083.60 8879.337 1621.138 
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 Raw statistical data: Intensity per unit AREA measurements for the point mutant 
 
Descriptive statistics 
 N Mean Std. Deviation Std. Error 
Point mutant 10 7385.70 424.287 134.171 
Age-matched control 1 10 18522.50 999.337 316.018 
Age-matched control 2 10 18778.50 1100.730 348.082 
Total 30 14895.57 5470.333 998.742 
 
 
 Post Hoc Tests 
 
Tukey HSD 
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 
Point mutant 
Age-matched control 1 -11136.800
*
 399.191 .000 
Age-matched control 2 -11392.800
*
 399.191 .000 
Age-matched control 1 
Point mutant 11136.800
*
 399.191 .000 
Age-matched control 2 -256.000 399.191 .799 
Age-matched control 2 
Point mutant 11392.800
*
 399.191 .000 
Age-matched control 1 256.000 399.191 .799 
 
Test of Homogeneity of Variances 
Intensity_per_area 
Levene Statistic df1 df2 Sig. 
2.154 2 27 .136 
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 Raw statistical data: Intensity per unit AREA measurements for the truncating 
mutant 
 
Descriptive statistics 
 N Mean Std. Deviation Std. Error 
Truncating mutant 10 17547.00 1373.949 434.481 
Age-matched control 1 10 18001.50 1787.682 565.315 
Age-matched control 2 10 17996.50 1820.943 575.833 
Total 30 17848.33 1629.010 297.415 
   
 
Post Hoc Tests 
 
Tukey HSD 
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 
Truncating mutant 
Age-matched control 1 -454.500 748.304 .817 
Age-matched control 2 -449.500 748.304 .821 
Age-matched control 1 
Truncating mutant 454.500 748.304 .817 
Age-matched control 2 5.000 748.304 1.000 
Age-matched control 2 
Truncating mutant 449.500 748.304 .821 
Age-matched control 1 -5.000 748.304 1.000 
 
Test of Homogeneity of Variances 
Intensity_per_area 
Levene Statistic df1 df2 Sig. 
.416 2 27 .664 
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